# CURRICULUM VITAE/BIBLIOGRAPHY

Sherine E. Gabriel, M.D., M.Sc., F.A.C.P.

# CURRENT ACADEMIC RANK & PROFESSIONAL POSITIONS

**University Professor of the Future of Health Outcomes and Medicine, &**

**Chair of the Arizona State University Health Outcomes Design Council** (August 2022-present)

**President Emeritus of Rush University** (July 2022-present)

**James A. Campbell Distinguished Professor Emeritus, Rush University** (July 2022-present)

**Dean and Professor of Medicine Emeritus, Rutgers Robert Wood Johnson Medical School** (October 2018 - present)

**Rutgers University Distinguished Professor Emeritus** (October 2018-present)

**Dean and Professor of Medicine Emeritus**, **Mayo Medical School** (May 2015-present)

# PAST ACADEMIC, PROFESSIONAL & LEADERSHIP POSITIONS

**President,** Rush University (February 1, 2019 – June 30, 2022)

**Chief Academic Officer**, Rush University System for Health (February 1, 2019 – June 30, 2022)

**The James A. Campbell Distinguished Professor**, Rush University (February 1, 2019 – June 30, 2022)

**CEO**, Robert Wood Johnson Medical Group (2015-2018)

**Dean,** Rutgers Robert Wood Johnson Medical School (2015-2019)

# Professor of Medicine, Rutgers Robert Wood Johnson Medical School (2015-2019)

**Rutgers University Distinguished Professor** (2017-2019)

**Dean, Mayo Medical School** (2012-2015)

# William J. and Charles H. Mayo Endowed Professor (2005-2015)

**Professor of Medicine** (Rheumatology) Mayo Medical School (2000-2015)

**Professor of Epidemiology** Mayo Medical School (2000-2015)

**Associate Professor of Epidemiology** (1995–2000)

**Associate Professor of Medicine** Mayo Medical School (1995–1999)

**Assistant Professor of Medicine** Mayo Medical School (1990–1995)

**Senior Associate Consultant** Mayo Clinic Department of Internal Medicine Division of Rheumatology (1990-1993)

**Senior Associate Consultant** Mayo Clinic Department of Health Sciences Research Section of Health Services Evaluation (1990–1993)

**Consultant** Department of Health Sciences Research, Division of Epidemiology (1993-2015)

**Consultant** Department of Internal Medicine Division of Rheumatology (1993-2015)

**Vice Chair** Department of Health Sciences Research (1997–2001)

**Chair** Department of Health Sciences Research Mayo Clinic (2001–2007)

**Medical Director** Mayo Clinic International Office (2007–2009)

**Medical Director** Mayo Clinic Office for Strategic Alliances and Business Development (2009–2011)

**Executive Board Member** Mayo Clinic, Rochester MN (2006–2009)

**Vice-Chair** Administrative Committee of the Executive Board (2006–2009)

**Vice-Chair** Strategy Development Support Group for the Executive Board (2007–2009)

**Vice-Chair** Mayo Clinic Business Development Council (2009–2010)

**Director of Education** Mayo Clinic Center for Translational Scientific Activities, CTSA (2006-2012)

# Adjunct Faculty Member Arizona State University (College of Health Solutions) (2013-2015)

# EDUCATION

**University/College**

9/75 - 6/76 University of Regina

Regina, Saskatchewan, Canada Pre-Medical Program

9/76 - 6/77 University of Saskatchewan

Saskatoon, Saskatchewan, Canada College of Pharmacy

# Medical School

9/77 - 6/82 College of Medicine, University of Saskatchewan Saskatoon, Saskatchewan, Canada

Doctor of Medicine, with Distinction: 05/20/82

# Internship

6/82 - 6/83 Rotating Internship

University of Manitoba Teaching Hospitals Winnipeg, Manitoba, Canada

# Residency

6/83 - 1/86 Residency - Internal Medicine

Mayo Graduate School of Medicine Rochester, Minnesota, USA

# Fellowship

1/86 - 1/88 Fellowship - Rheumatology

Mayo Graduate School of Medicine Rochester, Minnesota, USA

7/88 - 6/90 Rheumatology Research Fellowship Wellesley Hospital

Toronto, Ontario, Canada

7/88 - 6/90 M.Sc. in Clinical Epidemiology and Biostatistics: 11/09/90 McMaster University

Hamilton, Ontario, Canada

**Executive Education:** The Wharton School, University of Pennsylvania & the Kellogg School of Management, Northwestern University (each of the below was a one week residential program)

8/2000 Critical Thinking: *Real-World, Real-Time Decisions*

Aresty Institute of Executive Education

The Wharton School, University of Pennsylvania Philadelphia, Pennsylvania

9/2000 Managing People: *Power Through Influence*

Aresty Institute of Executive Education

The Wharton School, University of Pennsylvania Philadelphia, Pennsylvania

7/2002 Executive Negotiation Workshop: *Bargaining for Advantage*

Aresty Institute of Executive Education

The Wharton School, University of Pennsylvania Philadelphia, Pennsylvania

2/2010 Creating and Managing Strategic Alliances

Executive Programs, Kellogg School of Management Northwestern University

Chicago, Illinois

# BOARD CERTIFICATION(S)

LMCC - Licentiate of the Medical Council of Canada: 03/19/84 -#56,625

Diplomat - American Board of Internal Medicine: 09/10/86 - #107427

Diplomat - American Board of Internal Medicine/Rheumatology: 11/01/88 - #107427

American Board of Internal Medicine: 04/01/2014 - #107427

# MEDICAL LICENSURE

Minnesota Board of Medical Examiners License, Minnesota License #28383

# HONORS/AWARDS

1975 University of Saskatchewan Yearly Proficiency Award 1976 University of Saskatchewan Yearly Proficiency Award 1977 Logan Memorial Scholarship

1978 Logan Memorial Scholarship 1982 M.D. with Distinction

1988 Hench Award, Rheumatology 1988 Mayo Foundation Scholarship

1990 Clinician Involved in Research Award (CR 20), Mayo Foundation 1992 Clinician Involved in Research Award (CR 75), Mayo Foundation

1999 American College of Rheumatology Henry Kunkel Young Investigator Award 2000 MacMillan Management Scholar Award, Mayo Foundation

2005 William J. and Charles H. Mayo Endowed Professor

2006 Association for Clinical Research Training, Distinguished Educator Award

2006 McCann Scholar Award, Joy McCann Foundation, for excellence in mentoring in Science and Medicine 2006 Mayo Clinic 2006 Distinguished Educator Award

2007 Wallace Epstein Award for Training in Clinical Research, University of California, San Francisco 2007 Rain Visiting Professor Award, University of Nebraska Medical Center

2007 Certification of Appreciation, CTSA 2008 Certification of Appreciation, CTSA

2012 Certificate of Commendation, Patient-Centered Outcomes Research Institute

2016 Executive Women of New Jersey’s “Salute to the Policy Makers” award, May 5, 2016 2016 Elected Member, Association of American Physicians, *for the advancement of scientific*

*and practical medicine*

2017 Elected “Rheumatologist of the Year” for 2017, New Jersey Arthritis Foundation

2019 National Medical Fellowship Champions of Health: Excellence in Medical Education Award

(in support of underrepresented minority students in medicine and the health professions).

2020 Elected **National Academy of Medicine**

2020 Elected Member, The Chicago Network

2021 Elected Member, Women Business Leaders of the US Health Care Industry Foundation

2022 Alumni Lifetime Achievement Award, University of Saskatchewan

**LEADERSHIP ATTRIBUTES** *(excerpts from personnel files):*

## o Recognition For Clinical Practice

*“Her clinical judgment and compassionate care are above reproach”.*

*“She consistently demonstrated excellent clinical competence and judgment” “She is a superb clinician and her character is of the highest order”*

*“She has performed superbly as a member of our division and is greatly liked by her patients and colleagues. She is of the highest moral and ethical character.”*

*“Dr. Gabriel has been an outstanding experienced compassionate and thoughtful clinician with a large fund of knowledge of internal medicine and rheumatic diseases. She is an outstanding teacher and an internationally renowned researcher in rheumatic diseases and has been an exemplary standard bearer for Mayo Clinic in Health Sciences Research. Dr. Gabriel has impeccable integrity, a strong work ethic and is a highly motivated, thoughtful and experienced scientist and administrator.”*

## o Overall Performance

**Strategic Vision:** *“Dr. Gabriel is a leading thinker on patient centered health care”; “Dr. Gabriel is a visionary leader that is able to communicate that vision, [and] develop a strategy to achieve it”*

**Service Commitment:** *“Sherine is very committed to Mayo Clinic and its Service priorities”; “exceeds expectations of grants, publications, Education and Intramural service”; “She is unselfish in the use of her time for institutional needs”.*

**Organizational Alignment:** *“Dr. Gabriel is highly effective in aligning resources to achieve Mayo’s strategy and to increase efficiency”; “Dr. Gabriel’s reputation of excellence is well earned and well deserved.”*

**Business and Financial Acumen:** “*Sherine excels at financial management and makes feasible contingency plans to ensure she can weather any unavoidable gaps in research funding, minimize jeopardy to people’s jobs and to her research goals.”*

**Managing for Results:** *“Dr. Gabriel is very effective at management to achieve results”; “Sherine inspires loyalty and she fosters mutual accountability within teams by valuing each person’s contributions”*

**External Effectiveness:** *“Dr. Gabriel embodies effectiveness in extramural political activities”; “She has been extremely effective in professional associations, research and public activities, effectively enhancing the brand externally.”*

**Integrity & Professionalism:** *“Dr. Gabriel always conducts herself and her activities with utmost integrity and ethical values”’; “Sherine has a very high level of integrity and professional ethics. Excellence is her code of conduct and personal standard in all that she does”*

**Adaptability & Resourcefulness:** *“Dr. Gabriel remains flexible and is highly impervious to pressure and adversity in her extremely busy professional activities”; “Dr. Gabriel inspires great confidence in me and I feel that regardless of the situation, she is always constructive”*

**Fostering Mutual Respect:** *“Dr. Gabriel creates an atmosphere of collegiality among her team members and is able to appreciate differences while nurturing effectiveness and appropriate behavior.”; “Dr. Gabriel represents mutual respect when dealing with personnel conflicts by gaining the perspective of all participants. She maintains a high standard for her own behaviors and decisions and expects the same of others.”; “Sherine treats co-workers at all levels as equals and values their unique contributions.”*

**Seasoned Judgment:** *“She always makes calm, insightful, and well-reasoned comments at the Board.”; “Very mature judgment”; “Few people have better judgment.”*

**Consensus Building:** *“Dr. Gabriel is very effective at garnering consensus and support for collective actions and plans. I have learned much from watching how Dr. Gabriel solicits a range of inputs, finds common ground and moves the entire group forward.”*

**Attracting & Developing Talent:** *“Dr. Gabriel has been particularly effective in this arena.”; “Researchers from around the world want to work with and be mentored by Dr. Gabriel.”; “Sherine inspires and challenges people to achieve their maximum potential. She recognizes and fosters the development of talent.”*

**Developing Teams & Teamwork:** *“This is where Dr. Gabriel shines. I have met and interacted with only a few people that have the capabilities that she has in this regard.”; “Exceptionally Effective”*

**Facilitating Learning:** *“Her entire history at Mayo has demonstrated this competency.”; “This is a particular strength, and something which is a constant theme of Dr. Gabriel’s towards her mentees and her peers. She makes us all better at what we do.”; “Creates an environment that is empowering for individuals to learn and succeed.”*

**Mature Confidence:** *“Appears to be appropriately confident and shows strength in presenting her beliefs and convictions.” “Dr. Gabriel has demonstrated a willingness to appraise her performance and continue[s] to espouse strong convictions.”*

**“***Dr. Gabriel is in my view a very seasoned, mature leader who embodies the principles of Mayo Clinic, and who has the ability, vision and courage to lead us into the future.”*

*“Dr. Gabriel is a visionary and innovative leader who conducts herself with integrity and character in all her activities.”*

*“Dr. Gabriel’s leadership has been “healing”.*

# EXTRAMURAL BOARD & COMMITTEE SERVICE

**Service on Government Boards and Committees:**

**Member**, Special Review Committee for the Agency for Health Care Policy and Research for review of proposals of rheumatoid arthritis (PORTs), June 29, 1993, Arlington, Virginia.

**Member**, Health Care Technology Study Section, Agency for Health Care Policy and Research, July 1, 1993-June 30, 1997.

**Member**, Ad Hoc Study Section for National Institute of Arthritis and Musculoskeletal and Skin Diseases for review of RFA-AR-94-006 "Intravenous Antibiotics for Rheumatoid Arthritis", August 19, 1994, Arlington, Virginia.

**Invited Discussant**, NIH Workshop, September 12-13, 1994, Bethesda, Maryland: "TMJ Alloplastic Implants and Local/Systemic Responses: Observations and Research Needs."

**Member**, Ad Hoc Study Section for National Institute of Arthritis and Musculoskeletal and Skin Disease, for review of ARAMIS 2000 project, February 24, 1995, Bethesda, Maryland.

**Witness**, Joint Congressional Hearing, Subcommittee on Human Resources and Intergovernmental Relations and Subcommittee on National Economic Growth, Natural Resources and Regulatory Affairs. Subject: FDA Regulation of Medical Devices, Including the Status of Breast Implants. August 1, 1995, Washington, DC.

**Witness**, Legislative Commission on the Economic Status of Women, “Gender Bias in Health Care.” November 1, 1995, St. Paul, MN.

**Member**, Ad Hoc Study Section for National Institute of Arthritis and Musculoskeletal and Skin Disease, for review of program project grant, December 4, 1995, Bethesda, Maryland.

**Member**, Ad Hoc Study Section for National Institute of Arthritis and Musculoskeletal and Skin Disease, for review of MAMDC applications, July 1-3, 1996, Bethesda, Maryland.

**Witness**, U.S. House Committee on Government Reform and Oversight, Subcommittee on Government Management, Information, and Technology, Legislative Hearing on H.R. 52, the “Fair Health Information Practices Act of 1997.” June 5, 1997, Washington, DC.

**Member**, National Arthritis Data Work Group, National Institute of Arthritis Musculoskeletal and Skin Disease, 1997- 2002

**Member**, Special Review Committee for the Agency for Health Care Policy and Research for review of proposals “Quality of Care under Varying Features of Managed Care Organizations” March 26-27, 1998, Rockville, MD.

**Witness**, U.S. House Committee on Ways and Means, Subcommittee on Health: Patient Confidentiality, March 24, 1998, Washington, D.C.

**Member**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Fibromyalgia Review Group, December 1-2, 1998, Bethesda, MD.

**Member**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (Review Group), October 29, 1999, Rockville, MD.

**Member**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Data Safety Monitoring Board, “Randomized Double-Blind Active Treatment Controlled Trial of the Anti TNF-Antibody Infliximab in Patients with Early Rheumatoid Arthritis.” 2000

**Member**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Review Committee of K23, K24, and K25 awards entitled “A Mentored Patient-Oriented Research Career Development Award,” “Midcareer Investigator Development Award In Patient-Oriented Research,” and “Mentored Quantitative Research Career Development Award.” July 2001.

**Member**, NIAMS Review Committee of K23, K24, and K25 awards – 2001

**Participant/Speaker**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Extramural Roundtable: “Prevention Research in Arthritis and the Rheumatic Diseases.” February 20, 2002.

**Member**, NIAMS Data Safety Monitoring Board: 2002 – 2005

**Member**, NIH Committee for Specialized Centers of Research (SCOR) in Rheumatoid Arthritis: 2003 – 2005

**Member**, National Institutes of Health, Review Committee for Specialized Centers of Research (SCOR) in Rheumatoid Arthritis. 1/2003 – 5/2003.

**Participant**, National Institute of Arthritis and Musculoskeletal and Skin Diseases Extramural Roundtable: “Rheumatic Diseases.” February 26, 2003.

**Witness,** Technology, Biosciences and Medical Products Division, Commerce Committee, Minnesota House of Representatives, February 10, 2005, St. Paul, Minnesota.

**Member**, FDA/CDER Drug Safety and Risk Management Advisory Committee: 2010 – 2012

**Reviewer,** Neurology, Aging and Musculoskeletal Study Section, Center for Scientific Review, National Institutes of Health, October 4-5, 2011

**Chair,** FDA CDER Drug Safety, and Risk Management Advisory Committee, 2011-2013

**Member** National Arthritis and Musculoskeletal and Skin Diseases (NIAMS) **Advisory Council**, 2012-2016

**Member, Board of Directors,** Reagan-Udall Foundation for the FDA, 2013-2016

# Service on Non-Governmental Extramural Boards and Committees

**Member**, American College of Rheumatology Council on Health Care Research: 1994 - 1997

**Member,** Electoral Committee of the Mayo Foundation Chapter of Sigma Xi: May 1, 1995 - April 30, 1998

**Member**, Medical and Scientific Committee of the Minnesota Arthritis Foundation: 1991-1996

**Member**, Abstract Selection Committee of the American College of Rheumatology for Education, Health Services and Epidemiology for 1994 National Meeting

**Member**, American College of Rheumatology Bibliography Task Force on Cost and Outcomes of Rheumatologic Care, March 10-11, 1995

**Chair,** American College of Rheumatology Clinical Epidemiology Study Group 59th National Meeting, October 21- 26, 1995, San Francisco, CA

**Member**, Abstract Selection Committee of the American College of Rheumatology for Education, Health Services and Epidemiology, 60th National Meeting, October 18-22, 1996, Orlando, FL

**Chair,** American College of Rheumatology Clinical Epidemiology Study Group 60th National Meeting, October 18- 22, 1996, Orlando, FL

**Chair,** American College of Rheumatology Abstract Session “Economic Impact/Outcomes” 60th National Meeting, October 22, 1996, Orlando, FL

**Chair,** American College of Rheumatology Clinical Epidemiology Study Group, 61st National Meeting, November 8-12, 1997, Washington, DC

**Chair,** Abstract Selection Committee of the American College of Rheumatology for Education, Health Services and Epidemiology, 61st National Meeting, November 8-12, 1997, Washington, DC

**Member**, Behavioral/Epidemiology/HSR Study Section of the Arthritis Foundation, 1997-1999

**Chair,** OMERACT Economic Analysis in the Rheumatic Diseases Committee, 1997 – 2005

**Member**, Evidence Grading Review Work Group, Institute for Clinical Systems Integration, 1997-1998

**Member**, American College of Rheumatology Committee on Research, 1998-2001

**Member**, Immunex Data Safety Monitoring Board -- RECOVER & RENAISSANCE Trials: Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study of the Efficacy and Safety of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR: Fc) (etanercept) in Patients with Chronic Heart Failure (Class II-IV), 1998

**Chair,** American College of Rheumatology, Patient Based Research Ad-hoc Committee, 1999

**Co-Chair**, American College of Rheumatology Clinical Research Sub-Committee, 1999-2001

**Member**, Arthritis Foundation Medical and Scientific Committee, 2001–2002

**Member**, Arthritis Foundation Committee on Diversity, 2001

**Member**, AHC Clinical Research Forum Legislative Subcommittee, 2001

**Member**, Abbott Laboratories Scholarship Award Advisory Committee, 2001 – 2002

**Chair,** Abstract Selection Committee of the American College of Rheumatology for Epidemiology, Education, and Health Services Research, 65th National Meeting, November 10-15, 2001, San Francisco, CA

**Member**, Association of Clinical Research Training Program Directors, 2002 – 2003

**Member**, American College of Rheumatology Educational Products Committee, 2002 – 2003

**Member**, American College of Rheumatology Training and Workforce Committee, 2004 – 2005

**Member**, American College of Rheumatology Educational Products Committee, 2002 – 2005

**Member,** Board of Directors, American College of Rheumatology, 2002 – 2005

**Member**, American College of Rheumatology Strategic Governance Planning Committee, 2004 – 2006

**Chair**, American College of Rheumatology Quality Measures Committee, 2004 – 2006

**Member**, Institute for Work and Health of Canada, Scientific Advisory Committee, 2005 – 2007

**Member**, AAMC Advisory Panel on Research, 2006 – 2007

**Vice President**, American College of Rheumatology 11/2006 –10/2007

**Member, Board of Directors**, Research & Education Foundation of the American College of Rheumatology, 2006 – 2009

**Member,** External Advisory Board, University of Puerto Rico Post-doctoral Master of Science in Clinical Research Program, School of Medicine and School of Health Professions, 2006-2014

**Member,** Executive Board, Observational Medical Outcomes Partnership (OMOP), Foundation for the NIH, 2008 – 2012

**Member, External Advisory Board,** University of Iowa CTSA, 2008-2010

**Chair**, American College of Rheumatology Technology Leadership Council, 2007

**President-Elect**, American College of Rheumatology, 11/2007 – 10/2008

**President, American College of Rheumatology, 11/2008 – 10/2009**

**Chair**, American College of Rheumatology Committee on Nominations and Appointments, 2009 – 2010

**Member,** Institute of Medicine: Clinical Effectiveness Research Innovation Collaborative, 2009

**Chair**, American College of Rheumatology, Registries and Health Information Technology Committee (RHIT), 2011

**Member, External Research Education Advisory Board**, University Kentucky CTSA, 2011 – 2012

**Member, External Research Education Advisory Committee**, Georgetown University, 2011-2012

**Member, Oversight Board,** Wellcome Trust – HRB Dublin Centre for Clinical Research, 2011-2012

**Founding Chair, Methodology Committee, Patient-Centered Outcomes Research Institute (PCORI)**, 2010 -2013

**Member, International Coordinating Council**, Bone and Joint Decade/Initiative, 2010 –2014

**Member,** Center of Excellence in Regulatory Science & Innovation (CERSIs) (2015-2019)

**Trustee, New York Academy of Medicine (2017-2019)**

**Member,** Pharmacoepidemiology Advisory Board**,** Genentech, 2009-2019

**Member, Steering Committee,** Actemra Cardiovascular Outcomes Trial (ENTRACTE), Roche (2009-2018)

**Liaison,** Council of Deans to the Group of Education Affairs, (2014-2019)

**Member,** CCI, Inc. Center for Corporate Innovation, Inc. (2015-2020)

**Member** Wellcome/HRB Irish Clinical Academic Training program, Independent Advisory Board (2016-2020)

**Member,** Board of Directors, **Center for Women in Academic Medicine and Science, 2018-present**

**Member, Women Business Leaders of the U.S. Health Care Industry Foundation, 2020-present**

**Member, National Academy of Medicine** 2019-present

# Professional Society Memberships

Fellow American College of Rheumatology (#20880)

Fellow American College of Physicians-American Society of Internal Medicine

Member American Medical Association

Member Minnesota Medical Association

Member University of Saskatchewan College of Medicine Alumni Association

Member Mayo Alumni Association

Member Mayo Alumni Association - Hench Society

# Editorial Boards

**Associate Editor**, *Arthritis Care and Research,* 1997 - 2003

**Section Editor,** *Current Opinion in Rheumatology-Epidemiology and Health Services Research*, 1996 - 1998

**Advisory Editor,** *Arthritis & Rheumatism*, 1997 – 2006

**Readership Advisory Group,** *Annals of Internal Medicine*, 1999 – 2000 **Advisory Board**, *Nature Clinical Practice Rheumatology,* 2005 – present **Editorial Board**, *Annals of the Rheumatic Diseases*, 2007 – present **Editor,** *Kelley’s Textbook of Rheumatology,* 2009 - present

**Editorial Board,** *Nature Reviews Rheumatology,* 2005 - present

# Scientific Reviewer of the Following Medical Journals:

*American Journal of Epidemiology*

*American Journal of Kidney Diseases*

*American Journal of Medicine*

*Annals of Internal Medicine*

*Annals of the Rheumatic Diseases*

*Arthritis Care and Research*

*Arthritis Research and Therapy*

*Arthritis and Rheumatism*

*Arthritis Care and Research*

*British Medical Journal*

*Circulation*

*Drugs and Aging*

*Epidemiology*

*Gastroenterology*

*Journal of the American Medical Association*

*Journal of Bone and Mineral Research*

*Journal of Clinical Epidemiology*

*Journal of Epidemiology and Community Health*

*Journal of Gerontology*

*Journal of Rheumatology*

*Journal of the American Medical Association*

*Mayo Clinic Proceedings*

*Mayo Clinic Women’s Health Source*

*Medical Decision Making*

*Proceedings of the National Academies of Sciences*

*Nature Clinical Practice Rheumatology*

*New England Journal of Medicine*

*Osteoarthritis and Cartilage*

*Pharmacoeconomics*

*Post Marketing Surveillance: An International Journal on Pharmacoepidemiology*

*Quality of Life Research*

*Rheumatology*

*Scandinavian Journal of Rheumatology*

*Value in Health*

*Women's Health*

# INSTITUTIONAL, BOARD & COMMITTEE SERVICE

# Department of Internal Medicine, Research Committee: 1993 - 1997

# Department of Health Sciences Research, Research Committee: 1990 - 1996

# Division of Rheumatology, Research Committee: 1990 – 1999

# Division of Rheumatology, Education Committee: 1990 - 1999

# International Activities Committee: 1994 - 1997

**Vice Chair,** International Activities Committee: 1996 – 1997

International Activities Coordinating Committee: 1996 - 1997

**Chair,** Mayo Foundation Canadian Strategies Work Group: 1995 - 1997

Women's Advisory Council: 1995 - 1996

Rochester Marketing Committee: 1998 - 1999

Market Research Subcommittee: 1993 - 1996

Practice Analysis Committee: 1995 - 1996

Development Committee: 1996 - 1998

**Chair,** Credentials Committee, Sigma Xi, Mayo Chapter: 1996 – 1998

Member, Mayo Clinic Institutional Review Board: 1997 - 1999

**Chair,** Women’s Health Research Subcommittee: 1997 - 1999

**Chair,** Mayo Alumni, Balfour/Kendall Awards Selection Committee: 1997 - 1999

**Chair,** Master’s Degree in Clinical Research Task Force: 1997 - 1999 Mayo Clinic Rochester Research Committee: 1997 - 2008

**Vice Chair**, Mayo Clinic Rochester Research Committee: 2000 – 2001

Clinical Research Subcommittee: 1997 - 2001

Institutional Clinical Measurement Oversight Committee: 1998-1998

Research Executive Committee: 1998 - 2002

Research Personnel Subcommittee: 1998 – 1999

Research Strategic Issues Committee: 1999 – 2001

Research Operations Committee: 1999 - 2000

**Director,** Center for Patient-Oriented Research: 1999 – 2001

**Chair,** Strategic Alliances Committee: 1999 – 2001

Medical School Education Committee: 1999 - 2002

**Chair**, Mayo Clinical Research Training Program Executive Committee: 1999 - 2012

**Director**, Mayo Clinical Research Training Program: 1999 – 2012

Mayo Clinic Rochester **Board of Governors** Personnel Sub-Committee: 2000 - 2001

**Chair**, Health Sciences Research Operations Committee: 2000 – 2001

Fiscal Research Subcommittee: 2001

Genomics Task Force: 1999 – 2000

**Chair**, Department of Health Sciences Research Executive Committee: October 2000 – 2001

Thesis Advisory Committee for Victor M. Montori: 2001 – 2001

Genomics Coordinating Committee: 2002 – 2004

Genomics/Proteomics Oversight Group: 2002 – 2004

**Chair**, Bioinformatics Oversight Group: 2002 – 2004

Cancer Center Executive Committee: 2002 – 2003

Thesis Advisory Committee for Karen Mauck, MD: 2002 – 2003

Strategy Coordinating Group: 2003 – 2004

**Chair,** Thesis Advisory Committee for Dirk M. Nuenninghoff, MD: 2003

**Chair**, Thesis Advisory Committee for Paulo Nicola, MD: 2003 – 2005

Older Americans Independence Center (OAIC)

Mayo Internal Advisory Board: 2004

Mayo-IBM Oversight Committee: 2003 – 2004

Information Management and Technology Committee: 2004 – 2005

Information Management and Technology Executive Committee: 2004 – 2005

Rochester Finance Committee: 2004 – 2006

Mayo Rochester Director for Research Search Committee: 2005

Mayo Clinic Data Trust Sponsorship Group, 2005-2006

**Vice-chair**, Mayo Comprehensive Cancer Center Director Search Committee: 2005 – 2006

**Executive Board Member,** Mayo Clinic, Rochester MN, 2006 -- 2009

**Vice-Chair**, Administrative Committee of the Executive Board, 2006 – 2009

**Vice-Chair**, Strategy Development Support Group for the Executive Board, 2007 – 2009

Clinical and Translational Science Activities (CTSA) Executive Committee, 2005 – 2012

**Chair,** Clinical, and Translational Science Activities (CTSA) Education Executive Committee, 2005 – 2012

**Vice-Chair,** Mayo Clinic Research Committee, 2010 –2013

**Vice-Chair**, Mayo Clinic Business Development Council, 2009 – 2010

**Chair,** Internal Advisory Committee, Center for the Science of Health Care Delivery 2012 –2012

**Co-Chair**, Mayo Center for Clinical Investigation Task Force: 2001 – 2015

**Member**, Outcome Measures in Rheumatology (OMERACT) Steering Group, 2006 – 2015

**Member,** Rheumatology Research Committee: 2006 – 2015

**Member,** Scientific Advisory Group, Discovery Translation Program, 2010 – 2015

**Board Member,** Mayo Clinic Conflict of Interest Review Board 2010 – 2015

**Member,** Mayo Clinic Appointments and Promotions Committee 2011-2015

**Board Member**, Mayo Clinic Conflict of Interest Review Board (2010-2015)

**Member,** Mayo Clinic Appointments and Promotions Committee (2011-2015)

**Chair,** Mayo Clinic Advisory Committee, Center for the Science of Health Care Delivery (2012 -2015)

**Board Member,** Robert Wood Johnson University Hospital Board of Directors (2015-2019)

**Board Member**, Robert Wood Johnson University Hospital Foundation (2015-2019)

**Board Member**, Robert Wood Johnson University Hospital Board of Directors Finance Committee (2015-2019)

**Member**, Robert Wood Johnson University Hospital Executive Committee (2015-2019)

**Member**, Rutgers University, President’s Administrative Council (2015-2019)

**Member**, Internal Advisory Board, Rutgers Cancer Institute of New Jersey (2015-2019)

**Member**, NJ Acts (New Jersey Alliance for Clinical and Translational Science) (2017-2019)

**Member**, Robert Wood Johnson Barnabas Quality Committee (2016-2019)

**Chair,** Rush University Executive & Management Committee (2019-present)

**Chair,** Rush University Deans’ Council (2019-present)

**Co-chair (non-voting),** Rush University Board of Governors, *Chair: Carole Segal* (2019-present)

**Member (non-voting),** Rush University Health System Board of Trustees (2019-present)

**Member (non-voting),** Rush University Medical Center, Trustee Executive Committee (2019-present)

**Member (non-voting),** Rush University Health System Trustee Campaign Executive Committee (2019-present)

**Member (non-voting),** Rush University Health System Trustee Marketing and Communication Sub-Committee (2019-present)

**EDUCATIONAL ACTIVITIES**

**Curriculum/Course Development**

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students,

May 17, 1991

November 1, 1991

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students, "Descriptive Statistics."

March 20, 1992

April 30, 1993

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students, "Disease Frequency"

October 30, 1992

August 2, 1995

Preceptor, Department of Health Sciences Research, Section of Clinical Epidemiology, Continuing Education Seminars for Nurses, "The Gastrointestinal Risks Associated with NSAID Therapy." December 9, 1992

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students, "Meta-Analysis"

May 1, 1992

June 4, 1993

August 9, 1993

May 2, 1994

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students, “Screening.” May 5, 1995, Preceptor, Health Services Research 5000 Course Lecture, “Evidence-Based Medicine.”

May 8, 1997

May 7, 1998

Preceptor, Academic Skills Workshop for Junior Faculty, September 27, 1997, “Working with the Biostatistician.”

Preceptor, Department of Health Sciences Research, Section of Clinical Epidemiology, Continuing Education Seminars for Nurses, “Trends in the Incidence and Mortality of 2 Common Rheumatic Diseases: RA and SLE.” May 20, 1998

Preceptor, Mayo Medical School, Clinical Epidemiology Course, 3rd Year Students, "Decision Analysis"

May 22, 1997

May 21, 1998

August 4, 1999

Preceptor, Health Sciences Research 5390 Course “Epidemiology of the Musculoskeletal Diseases”

July-September, 2001

March-May, 2004

February-March, 2006

**Founding Director**, Mayo Clinic Clinical Research Training Program 1997-2005

**Founding Director of Education and Co-PI**, Mayo Clinic Clinical and Translational Science (CTSA) 2005-2015

# Teaching Activities

Moderator and Presenter, Practice of Internal Medicine, Mayo Clinic, May 15, 1992, "Rheumatology Update, 1992."

Department of Physical Medicine and Rehabilitation, Resident Basic Science Course Lecture Series, March 26, 1993, "Nonsteroidal Anti-Inflammatory Drugs: An Overview."

Department of Internal Medicine, Division of Rheumatology, Research Conference, April 22, 1993, "The Means to An End."

The practice of Internal Medicine, Mayo Clinic, May 14, 1993, "Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs.”

Department of Dermatology, Hospital Conference, September 2, 1993, "Adverse Effects of NSAIDs."

Medical Grand Rounds, November 17, 1993, "Risk of connective tissue disease following breast implants: A population-based 1964-1991 cohort study.”

Strategic Alliances Committee meeting with Hoechst-Roussel Pharmaceutical, November 29-30, 1993, "Opportunities for collaborative research at Mayo.”

Department of Internal Medicine, Core Curriculum Presentation, December 7, 1993, "Adverse Effects of NSAIDs."

1994 Interdisciplinary Arthritis Rehabilitation Committee, Postgraduate Advances in Arthritis for Health Professionals, February 22, 1994, "Treatment of Arthritis.”

The practice of Internal Medicine, May 13, 1994, "Silicone breast implants and connective tissue disease."

Department of Health Sciences Research, Section of Clinical Epidemiology, Continuing Education Seminars for Nurses, September 28, 1994, "The Mayo Breast Implant Study: An Update."

Division of Rheumatology Research Seminar, August 25, 1994, "Practice Variation."

Health Sciences Research Departmental Seminar, November 21, 1994, "Costs of arthritis: Estimates from a geographically defined population."

Division of Rheumatology Research Seminar, July 13, 1995, “Cost of arthritis: Estimates from a geographically defined population.”

Department of Anesthesiology Lecture, January 24, 1996, “The Breast Implant Controversy: The Science, the Media, and the Law.”

36th Annual Mayo Clinic Dental Reviews Program, March 15-16, 1996, “Breast Implants and Connective Tissue Disorders - Is there a Risk?”

Division of Rheumatology Research Seminar, September 12, 1996, “Relation of Dietary Intake and Serum Levels of Vitamin D to Progression of Osteoarthritis of the Knee among Participants in the Framingham Study.”

Regional Visiting Faculty Program, Immanuel-St. Joseph’s Hospital, September 17, 1996, “Adverse effects of NSAIDs.”

Mayo Research Society, December 10, 1996, “The Breast Implant Controversy: A complex Interplay between Science and the Law.”

Division of Rheumatology Research Seminar, Mayo Foundation House, January 23, 1997, “Outcome in Rheumatoid Arthritis: Are we really making an Impact?”

The Second Women in Medicine: Personal Growth and Professional Development. Mayo School of Continuing Education, May 15-17, 1997. “Overcoming Gender-Based Obstacles.”

Division of Rheumatology Research Seminar, January 16, 1998, "The Clinical Research Subcommittee--An Overview."

Division of Rheumatology Research Seminar, March 19, 1998, “Mortality in RA: Have we made an Impact in 3 Decades?”

Division of Rheumatology Research Seminar, May 15, 1998, “Report of the OMERACT Task Force on Economic Evaluation in Rheumatology.”

Division of Rheumatology, Rheumatology Research Seminar, February 19, 1999, “Heart Disease in Rheumatoid Arthritis.”

Division of Rheumatology, Rheumatology Research Seminar, June 11, 1999, “Modeling the Lifetime Costs of Rheumatoid Arthritis.”

Women's Healthcare Council, June 14, 1999, "The Women's Healthcare Research Subcommittee - Accomplishments and Future Plans."

Mayo New Staff Orientation, October 28, 1999, “Overview of Research at Mayo Clinic Rochester.”

Minnesota House of Representatives, Health and Human Services Committee, November 10, 1999, “Overview of Research at Mayo Clinic Rochester.”

Department of Neurology Research Committee, January 12, 2000, “Center for Patient-Oriented Research.” Mayo All Staff Leadership Meeting, January 14, 2000, “Overview of Research at Mayo Clinic Rochester.”

Division of Rheumatology, Rheumatology Research Seminar, February 4, 2000, “Is rheumatoid arthritis care more costly when provided by rheumatologists compared to generalists?”

Department of Dental Specialties staff meeting, March 15, 2000, “Center for Patient-Oriented Research.”

Division of GIH Staff meeting, Department of Internal Medicine, May 2, 2000, “Overview of Research at Mayo Clinic Rochester.”

Brown Bag Session, June 13, 2000, “The Center for Patient-Oriented Research and the General Clinical Research Center.”

Department of Physical Medicine & Rehabilitation Grand Rounds, July 25, 2000, “Center for Patient-Oriented Research.” Division of Rheumatology, Rheumatology Research Seminar, August 18, 2000, “Heart Disease in Rheumatoid Arthritis.”

Department of Health Sciences Research, Section of Clinical Epidemiology (Seminar), September 5, 2000, “Heart Disease in Rheumatoid Arthritis.”

Department of Health Sciences Research, Section of Clinical Epidemiology (Seminar), October 3, 2000, “The Value of Research in Academic Medicine: The Patients’ Perspective.”

Division of Rheumatology, Rheumatology Research Seminar, September 7, 2001, “Trends in Incidence and Mortality in Rheumatoid Arthritis in Rochester, Minnesota over a 40-Year Period.”

Department of Health Sciences Research Seminar, September 17, 2001, “Trends in Incidence and Mortality in Rheumatoid Arthritis in Rochester, Minnesota over a 40-Year Period.”

Mayo Rochester Clinical Research Subcommittee, March 14, 2002, “The Value of Research in Patients’ Choice of a Medical Center.”

Administrative Committee on the Board of Governors, May 21, 2002, “The Mitchell Stem Cell Report.”

Department of Health Sciences Research Seminar, January 6, 2003, “Cost and Quality Consequences of Rheumatologist vs. Non-Rheumatologist Care for Patients with Polymyalgia Rheumatica.”

Presenter, **“Why Patients Choose Mayo”**

* Mayo Clinic Rochester Board Administrative Committee, March 26, 2002
* Mayo Clinic Rochester Board of Governors Meeting, March 28, 2002
* Mayo Clinic Clinical Practice Committee Meeting, May 7, 2002
* Mayo Clinic Brown Bag Seminar Series, May 13, 2002
* Foundation Research Advisory Committee, May 15, 2002
* Mayo Clinic Rochester Department of Medicine Executive Committee, June 6, 2002
* Mayo Clinic Rochester, Division of Gastroenterology and Hepatology, July 16, 2002
* Mayo Clinic Rochester, Division of Rheumatology Staff Conference, July 18, 2002
* Mayo Clinic Rochester, Department of Obstetrics and Gynecology Executive Committee, August 19, 2002
* Mayo Clinic Rochester, Department of Obstetrics and Gynecology Staff Meeting, September 23, 2002
* Mayo Clinic Rochester Research Committee, October 4, 2002
* Mayo Clinic Research Communications Subcommittee and Foundation Education Communications Subcommittee, November 6, 2002
* Mayo Clinic Rochester, Department of Pediatrics Research Forum, November 22, 2002
* Mayo Managed Care Leadership Conference, August 12, 2003
* Mayo Clinic Rochester, Division of Communications, February 24, 2004

# Presenter, “The Mayo Clinical Research Training Program:”

* Mayo Graduate School Education Committee, October 7, 1998,
* Mayo Graduate School of Medicine Education Committee, October 8, 1998
* Mayo Foundation Education Committee, December 18, 1998
* Department of Internal Medicine, Outcomes Research Group, March 8, 1999
* Department of Health Sciences Research, Clinical Epidemiology Seminar, March 8, 1999
* Division of Cardiovascular Diseases, Cardiovascular Education Committee, June 15, 1999
* Mayo Graduate School Education Committee, June 16, 1999
* Subcommittee on Subspecialty Training, Dept. of Internal Medicine, September 14, 1999
* Hematology Research Committee, Department of Internal Medicine, September 27, 1999
* Medical Oncology Conference, Department of Oncology, November 9, 1999
* Third Annual Cardiovascular Fellows Research Retreat, November 19-20, 1999
* Clinical Investigators Meeting, September 13, 2000
* Mayo Clinic Brown Bag Session, September 20, 2000
* Mayo Clinic Brown Bag Session, May 15, 2001
* Department of Preventive and Occupational Medicine, May 17, 2001
* Department of Surgery, June 5, 2001
* K30 Internal Advisory Committee, May 15, 2002
* K30 External Advisory Committee, June 18, 2002
* Research Education Committee, January 13, 2003
* Mayo Clinic GCRC Research Forum, February 24, 2003
* Department of Neurology, Scholarship Leadership Team, May 20, 2003
* Mayo Rochester Clinical Research Subcommittee, June 13, 2003
* Mayo Graduate School of Medicine Subspecialty Training Meeting, July 8, 2003
* Clinical Research Training Program Career Development Forum, August 12, 2003
* Department of Education Services, Education Executive Subcommittee, August 25, 2003
* Department of Pediatrics – Grand Rounds, July 16, 2004 Presenter, **“Mayo Clinic’s Clinical Research Scholars Program:”**
* Division of Biostatistics, November 12, 2004
* Department of Surgery, November 15, 2004
* Department of Neurology, November 18, 2004
* Department of Medicine, November 18, 2004
* Research Committee, December 3, 2004

Genomics in Clinical Practice – Genetic Testing: Past, Present & Future, October 7, 2003, “Bioinformatics and Informatics at Mayo Clinic.”

Mayo Clinic Jacksonville, February 6, 2004, “The Department of Health Sciences Research at Mayo Clinic Rochester: Opportunities for Collaboration with Mayo Clinic Jacksonville”

Mayo Clinic Department of Health Sciences Research Seminar, August 30, 2004, “Heart Disease in Rheumatoid Arthritis.”

Mayo Clinic College of Medicine, February 27, 2006, “Leadership Principles for Clinical Research in the 21st Century: Creating an Effective Partnership between the Researcher and the Administrator.”

Mayo Clinic College of Medicine, February 27 – March 23, 2006, “The Epidemiology of Musculoskeletal Diseases.”

Mayo Clinic Department of Health Sciences Research Seminar, September 18, 2006, “Cardiovascular Risks of NSAIDS: An example of an inadequate Drug Safety Surveillance System.”

Mayo Clinic/University of Puerto Rico Course, University of Puerto Rico, San Juan. January 22, 2007, “What is Clinical Research and Why is it Important?”

Mayo Clinic College of Medicine, February 9, 2009, “Leadership Principles for Clinical Research in the 21st Century: Creating an Effective Partnership between the Researcher and the Administrator.”

Medical Grand Rounds, May 26, 2010, “Health Care Reform: Implications for Mayo Clinic.”

Mayo Clinic Center for Clinical and Translational Science, February 17, 2012, “Enhancing Value in Healthcare: The Strategic Role of Outcomes Research.”

Rheumatology Division Conference, July 2013. “Enhancing Value in Musculoskeletal Care by: Integrating Research with Practice to Advance Science and Improve Health.”

Medical Grand Rounds, September 25, 2013, “Outcomes Research Institute and PCORI Methodology Committee: PCORI Working Differently for Patients.”

# Mentorships: *I have provided mentoring for the following individuals:*

|  |  |  |
| --- | --- | --- |
| Antonio A. Achkar, MD | 1993 | Rheumatology Fellow |
| Carlo Salvarani, MD | 1993 | Rheumatologist |
| Mohammed I. Shbeeb, MD | 1994 | Rheumatology Fellow |
| Jay Sunku, MD | 1994-1995 | Rheumatologist |
| Lynne Peterson, MD | 1995 | Rheumatology Fellow |
| Iris Heid, M.Sc. | 1995 | Data Analyst |
| Regina Taylor, MD | 1995 | Rheumatology Fellow |
| Michael Farkouh, MD | 1995-1996 | Internist |
| Julian Thumboo, MD | 1997 | Rheumatologist |
| Veronique Roger, MD | 1997-1999 | Cardiologist |
| Kristine Uramoto, MD | 1997-1998 | Rheumatology Fellow |
| Mia Teresa Cuddihy, MD | 1997-1999 | General Internist |
| Pedro Caraballo, MD | 1998 | Endocrinology Fellow |
| Anthony French, MD | 1998-1999 | Rheumatology Fellow |
| Ann Proven, MD | 1998-1999 | Research Fellow, Rheumatologist |
| Tousif Pasha, MD | 1998-1999 | GI Fellow |
| Emvalee Arromdee, MD | 1998-1999 | Rheumatology Fellow |
| Michelle Doran, MD | 1999-2001 | Research Fellow, Rheumatologist |
| Jeanne Huddleston, MD | 2000-2001 | General Internist |
| Celia Kamath, PhD | 2000-2001 | Special Project Associate |
| Michele Bidaut-Russell, PhD | 2000-2001 | Research Associate |
| Stephanie Carlson, MD | 2000 | Radiologist |
| Hilal Maradit Kremers, PhD | 2001-2008 | Research Associate |
| Victor Montori, MD | 2001 | Endocrinology Fellow |
| Paulo Nicola, MD | 2003-2007 | Research Fellow, Rheumatologist |
| Angel Gonzalez, MD | 2004-2006 | Research Fellow, Rheumatologist |
| John M. Davis, III, MD | 2004-2010 | Research Fellow, Rheumatology Faculty |
| Tim Bongartz, MD | 2005-2009 | Research Fellow, Rheumatology Faculty |
| Kenneth J. Warrington, MD | 2006-2010 | Rheumatology Faculty |
| Yimy Medina, MD | 2006-2007 | Rheumatology Fellow |

|  |  |  |
| --- | --- | --- |
| Serguei Pakhomov, MD | 2006-2008 | Informatics Faculty |
| Kimberly Liang, MD | 2005-2009 | Rheumatology Fellow |
| Jasvinder Singh, MD | 2006-2009 | Research Trainee (K12), Rheumatologist |
| Jeanne Huddleston, MD | 2006-2014 | Research Trainee (K12) |
| ***Thesis Committee Advisor:*** |  |  |
| Carlotta Nannini, MD | 2007 | Rheumatology Fellow |
| Deana Hoganson, MD | 2007-2009 | Rheumatology Fellow |
| Tanaz Kermani, MD | 2007-2011 | Rheumatology Resident |
| Valentin S. Shafer, MD | 2007-2008 | Rheumatology Fellow |
| Floranne C. Ernste, MD | 2007-2011 | Rheumatology Faculty |
| Vaidehi Chowdhary, MD | 2007-2010 | Rheumatology Faculty |
| Murat Icen, MD | 2007-2009 | Research Fellow, Internist |
| Stephanie Reading | 2008 | Public Health Student |
| Shreyasee Amin, MD | 2008-2011 | Rheumatology Faculty |
| Elena Myasoedova, MD, PhD | 2008-2010 | Fulbright Scholar, Rheumatologist |
| Irene Whitt, MD | 2009-2010 | Rheumatology Fellow |
| Courtney Shourt, MD | 2009-2011 | Rheumatology Resident |
| A. Kirsten Bacani, MD | 2009-2012 | Rheumatology Fellow |
| Megan Krause, MD | 2010-2012 | Internal Medicine Resident |
| Melissa Wells, MD | 2010-2012 | Internal Medicine Resident |
| Sara McCoy, MD | 2010-2012 | Internal Medicine Resident |
| Krati Chauhan, MBBS | 2012-2013 | Rheumatology Resident |
| Elena Myasoedova MD | 2013-2015 | Fulbright Scholar & Rheumatology Resident |
| Soko Setaguchi | 2016-2018 | Internal Medicine Resident/Junior faculty |

**Education Scholarship**

**EDUCATION GRANTS AWARDED**

Title: Biomedical Research Support Program for Medical Schools - Center for Patient Oriented Research (CPOR)

# Principal Investigator: John C. Burnett

**Principal Investigator of CPOR Education Core: Sherine E. Gabriel, M.D., M.Sc.**

Funding Source: Howard Hughes Medical Institute Funding Amount: **$452,637**

Years: 01/10/2000 – 12/31/2003

Title: The Next Generation of Clinical Investigators at Mayo Clinic

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Dr. Ralph and Marian C. Falk Medical Research Trust Funding Amount: **$577,000**

Years: 03/01/2000 – 02/28/2003

Title: CPOR Phase II Capital and Operating Expenses

# Principal Investigator of CPOR Education Core: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Ahmanson Foundation Funding Amount: **$250,000**

Years: 05/01/2000 – 04/30/2001

Title: Rappaport Center for Patient Oriented Research **Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.** Funding Source: Rappaport

Funding Amount: **$568,064**

Years: 05/01/2000 – 04/30/2001

Title: Multidisciplinary Training Grant – Rheumatologic Disease

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: NIAMS T32 AR007610-04 Funding Amount: **$190,616**

Years: 05/01/2001 – 04/30/2006

Title: The Pfizer New Investigator Award **Director: Sherine E. Gabriel, M.D., M.Sc.** Funding Source: Pfizer, Inc.

Funding Amount: **$200,000**

Years: 01/01/2002 – 12/31/2003

Title: Clinical Genomics Visiting Professorship Program

# Director: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Pfizer, Inc. #97 Funding Amount: **$72,800** Years: 10/01/2002 – 09/30/2004

Title: The Mayo Clinical Research Training Program

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. – 25% effort

Funding Source: NIH/NCRR – 9 K30 RR022296 Funding Amount: **$1,200,000**

Years of Study: 06/01/1999 – 06/29/2006

Title: Multidisciplinary Clinical Research Career Development Program **Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. – 20% effort** Funding Source: NIH/NCRR 8 K12 RR023263

Funding Amount: **$15,146,403**

Years of Study: 09/23/2004 – 09/29/2006

Title: Mayo Clinic Center for Clinical and Translational Scientific Activities (CTSA)

# Co-Principal Investigator & Director of Education: Sherine E. Gabriel, M.D., M.Sc. – 45% effort

Funding Source: NIH/NCRR UL1 RR 02415

Funding Amount: **$72.6M (Education Budget: $23.6 Million)**

Years of Study: 09/30/2006-06/30/2011

Title: Mayo Clinic Center for Clinical and Translational Scientific Activities (CTSA)

# Co-Principal Investigator & Director of Education: Sherine E. Gabriel, M.D., M.Sc. – 0% effort

Funding Source: NIH/NCRR UL1 RR 024150

Funding Amount: **$64.6 M (Education Budget: $24.0 Million)**

Years of Study: 07/01/2011-06/30/2016

Title: Accelerating change in Medical Education: Optimizing student readiness for medical practice and life-long learning

**Principal Investigator:** **Sherine E. Gabriel, M.D., M.Sc.**

Co-Principal Investigators: Robert E. Nesse, MD, Lotte N. Dyrbye, MD Funding Source: American Medical Association

Funding Amount: **$1.0 M**

Years of Study: 9/1/2013 – 8/31/2018

Title: Rapidly Disseminating Science of Health Care Delivery Knowledge for Maximal Impact Principal Investigator: **Sherine E. Gabriel, M.D., M.Sc.**

Funding Source: Kern Family Foundation Funding Amount: **$3.0 M**

Years of Study: November 1, 2013 – March 31, 2017

# RESEARCH GRANTS AWARDED

Title: A Proposal for A Cost Utility Analysis Of Misoprostol Prophylaxis For NSAID Induced Ulcers, #510-89.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 20% effort

Funding Source: Mayo Foundation CR-20 Award Funding Amount: $73,987

Years of Study: 02/01/1990 – 01/01/1992

Title: The Health Care Costs Of Arthritis Patients Compared To Non-Arthritis Patients - A Community Based Study,

#390-91.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 0% effort

Funding Source: Minnesota Arthritis Foundation Funding Amount: $17,000

Years of Study: 01/01/1992 – 12/31/1992

Title: Silicone Breast Implants and Autoimmune Disorders: A Population-Based Retrospective Cohort study, 1962- 1991, #PSEF, IRB#179-92.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 10% effort

Funding Source: Plastic Surgery Education Foundation Funding Amount: $174,060

Years of Study: 08/01/1992 – 07/31/1993

Title: Gender Differences in the Utilization of Total Hip Arthroplasty: A Population Based Study in Olmsted County, MN, 1985-1990.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 0% effort

Funding Source: Mayo Clinic, Division of Rheumatology Funding Amount: $3,000

Years of Study: 11/1/1992 – 10/31/1993

Title: A Cost-Utility Analysis Of Prophylaxis For NSAID Induced GI Events, #423-90.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 50% effort

Funding Source: Mayo Foundation CR-75 Award Funding Amount: $536,348

Years of Study: 01/01/1992 – 12/31/1994

Title: Trends in Survival and Comorbidity among Persons with Arthritis between 1965-1995, #468-92.

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 0% effort

Funding Source: Minnesota Arthritis Foundation Funding Amount: $11,123

Years of Study: 01/01/1993 – 12/31/1994

Title: Evaluation of Osteoporosis Prevention in Elderly Women

# Principal Investigator/Mayo Subcontract: Sherine E. Gabriel, M.D., M.Sc. - 10% effort

Funding Source: NIA R01-AG12262-01A1

Funding Amount: Mayo Subcontract $200,317; Total $642,098 Years of Study: 01/01/1995 – 12/31/1997

Title: Outcomes and Management of Acute Chest Pain

# Co-Principal Investigator: Sherine E. Gabriel, MD, M.Sc. - 15% effort

Funding Source: AEtna #1-1 Funding Amount: $1,048,296

Years of Study: 01/01/1995 – 12/31/1997

Title: Consequences of Arthritis Comorbidity with Aging

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 15% effort

Funding Source: Arthritis Foundation AF#15-1 Funding Amount: $218,267

Years of Study: 07/01/1995 – 06/30/1998

Title: Primary Care for the Chronically Ill: Specialists vs. Generalists. **Principal Investigator: Sherine E. Gabriel, MD, M.Sc. - 25% effort** Funding Source: Mayo

Funding Amount: $327,694

Years of Study: 11/1/1995 – 06/01/1999

Title: A Comparison of Orthopedists and Non-Orthopedists in the Management of Acute Knee Injuries

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc. - 10% effort

Funding Source: American Academy of Orthopedic Surgeons (AAOS) 1A1737#2-1 Funding Amount: $158,661

Years of Study: 02/01/1996 – 01/31/1998

Title: Gene Mapping in Women with Systemic Lupus Erythematosus **Principal Investigator/Mayo Subcontract: Sherine E. Gabriel, M.D., M.Sc.** Funding Source: NIAID AI43274-03

Funding Amount: Mayo Subcontract $157,996 Total $2,922,432 Years of Study: 09/30/1996 – 09/29/2000

Title: Evaluation of Osteoporosis Prevention in the Elderly

# Principal Investigator/Mayo Subcontract: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: NIH NIA 2 R01-AG12262-04 Funding Amount: $1,191,965

Years of Study: 12/01/1998 – 11/31/2001

Title: Long-Term Outcomes in Rheumatoid Arthritis: A Population-Based Assessment – IRB #407-99

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Immunex Corporation #5-1 Funding Amount: $340,869

Years of Study: 05/01/1999 – 04/30/2001

Title: The Cost and Quality Consequences of Rheumatologist vs. Non-rheumatologist Care for Patients with Polymyalgia Rheumatica

**Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.** Funding Source: National Arthritis Foundation #19 Funding Amount: $446,615

Years of Study: 09/01/1999 – 08/31/2003

Title: The Cost-Effectiveness of Ibuprofen, Selective Cox-2 Inhibitors and Tylenol in the Treatment of Symptomatic Knee Osteoarthritis

# Principle Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: McNeil Pharmaceutical #18

Funding Amount: $106,777

Years of Study: 09/01/2000 – 07/31/2001

Title: The Pfizer New Investigator Award **Director: Sherine E. Gabriel, M.D., M.Sc.** Funding Source: Pfizer, Inc.

Funding Amount: $200,000 Years: 01/01/2002 – 12/31/2003

Title: Osteoporosis Prevention in Elderly: Benefits and Costs

# Co-investigator: Sherine E. Gabriel, M.D., M.Sc.

(PI: Tosteson ANA / Vanness D)

Funding Sources: NIH/NIA R01 AG12262 Funding Amount: $55,254

Years: 07/02/2002 – 06/30/2007

Title: Clinical Genomics Visiting Professorship Program

# Director: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Pfizer, Inc. #97 Funding Amount: $72,800 Years: 10/01/2002 – 09/30/2004

Title: Health Economics in Rheumatology: An International Conference

# Director: Sherine E. Gabriel, M.D., M.Sc.

Funding Sources NIH (R13), Centocor, Abbott, AstraZeneca, McNeil

Funding Amount: $41,000 NIH; Centocor $10,000; Abbott $10,000; AstraZeneca $20,000; McNeil $10,000

Title: Rheumatoid Arthritis and the Risk of Serious Lower Gastrointestinal Events

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: Roche Pharmaceuticals Funding Amount: $1,064,442

Years of Study: 12/15/07-12/14/2010

Title: Trends in Serum Lipid Profile in Rheumatoid Arthritis - A population-based analysis Role: **Co-Investigator: Sherine E. Gabriel, M.D., M.Sc.**

Funding Source: Roche Pharmaceuticals Funding Amount: $164,997

Years of Study: 09/15/08-02/28/2010

Title: Heart Disease in RA

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: NIH R01 AR46849 Funding Amount: $1,250,000

Years of Study: 09/01/2000 – 03/31/2011

# Principal Investigator: Sherine E. Gabriel, M.D., M.Sc.

Funding Source: NIH R01 AR46849 Funding Amount: $2,105,021

Years of Study: 3/01/2012 – 02/28/2017 Priority Score 14, 7th percentile

*In addition, I have served as a consultant/mentor on the following awards:*

Education:

Eli Lilly and Company Career Development Award in Postmenopausal Women’s Health Principal Investigator: Maria-Teresa Cuddihy, MD

Funding Source: Eli Lilly

Cardiovasology

Principal Investigator: John C. Burnett, M.D. Funding Source: NIH HL07111

Mayo Rehabilitation Research Training Center Principal Investigator: Jeffrey R. Basford, M.D. Funding Source: NICHH 5T32HD007447-09

Mayo Cancer Genetic Epidemiology Research Training Program Principal Investigator: Thomas Sellers, PhD

Funding Source: NIH R25CA92049

Development of a Course in Clinical Decision Making Principal Investigator: John Bundrick, M.D.

Funding Source: Mayo CE10 Award

Mayo Clinical Oncology Research Training Program Principal Investigator: Lynn Hartmann, M.D. Funding Source: NIH 1K12CA090628

K30 Clinical Research Training Program

Principal Investigator: Larry Moreland, M.D. University of Alabama Funding Source: NIH 5K30HL004146

Postdoctoral Master of Science in Clinical Research

Principal Investigator: Estela S. Estape (University of Puerto Rico) Funding Source: NIH R25RR017589

Center for Translational Nanotechnology in Cancer Principal Investigator: Franklyn G. Prendergast, M.D., Ph.D. Funding Source: NIH U54CA119354

Mayo Clinic Emergency Medicine Clinical Research Training Program Principle Investigator: Dr. Allan Jaffe

Funding Source: NIH GRANT10707412

# Research

Long-term Outcomes of Children Who Have Had Juvenile Rheumatoid Arthritis: A Population-Based Study. Principal Investigator: Lynne S. Peterson, M.D.

Funding Source: Arthritis Foundation - Minnesota Chapter

A Population-Based Case-Control Study of Ethnic Differences in the Utilization of Hip and Knee Replacement Surgery for the Treatment of Arthritis

Principal Investigator: Augustin Escalante, M.D. Funding Source: Health Care Financing Administration

A Clinical Practice Intervention to Improve Osteoporosis Management in Olmsted County Residents Sustaining a Distal Forearm Fracture

Principal Investigator: Marie-Teresa Cuddihy, M.D. Funding Source: Practice Development 20/20 Award

Development of Breast Cancer Research Program at Mayo (P20) Core--Clinical Trial Protocol Review and Monitoring System Principal Investigator: James N. Ingle, M.D.

Funding Source: NCI 3P30CA015083

Osteopenia in Adults with a History of Juvenile Rheumatoid Arthritis Principal Investigator: Anthony French, M.D.

Funding Source: Merck #US-56 & Mayo CR Award

Program to facilitate diagnosis and treatment of osteoporosis after hip fracture Principal Investigator: Mark Bolander, M.D.

Funding Source: Merck #150

Planning Grant for Multipurpose Clinical Research Centers (MCRCs) Principal Investigator: Richard M. Silver, M.D.

Funding Source: NIH 1 P20 AR46675-01

Planning Grant for Multipurpose Clinical Research Centers (MCRCs)

Principal Investigator: Richard M. Silver, M.D. (Medical University of South Carolina) Funding Source: NIH 1 P20 AR46675-01

Development of a Clinical Trials Program in Colon and Rectal Surgery Principal Investigator: Heidi Nelson, M.D.

Funding Source: Mayo CE10 Award

Clinical Research of Infections in Transplantation Principal Investigator: Carlos Paya, M.D. Funding Source: NIH 1K24A101836

NHLBI Respiratory Biology Research Training Program Principal Investigator: Andrew Limper, M.D.

Funding Source: NIH T32HL007897

Assessments of Quantitative Function in Motor Neuron Diseases Principal Investigator: Eric Sorenson, M.D.

Funding Source: NIH 5K23NS002182

Myocardial Infarction in the Population Principal Investigator: Veronique Roger, M.D. Funding Source: NIH 5K24HL068765

Adverse Cardiac Events after Hip Surgery Principal Investigator: Jeanne Huddleston, M.D. Funding Source: AHA 03-301-03-N1

Coronary Endothelial Function in Humans Principle Investigator: Amir Lerman, M.D. Funding Source: NIH K24 HL69850

# INVITED PRESENTATIONS, Regional, National & International

1. University of Minnesota, School of Public Health, Minneapolis, Minnesota, February 28, 1991. "Cost Utility Analysis of Prophylaxis for NSAID Induced GI Events.”
2. Olmsted Medical Group, May 14, 1992. “Cost Utility Analysis of Prophylaxis for NSAID Induced GI Events.”
3. Hospital Central Norte, Mexico City, Mexico, September 2, 1992. "Gastrointestinal Risks Associated with NSAID Therapy."
4. Grand Rounds, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, February 4, 1994. "Misoprostol prophylaxis for NSAID-induced adverse gastrointestinal events: Is it worth it?"
5. OMERACT II, Ottawa, Canada, June 30 - July 2, 1994. "Economic evaluation using mathematical models: The case of misoprostol prophylaxis."
6. Third International Symposium on Osteoarthritis, Val David, Quebec, Canada, October 5 - 7, 1994. "Costs of osteoarthritis: Estimates from a geographically-defined population."
7. Minnesota Chapter of the American College of Surgeons Annual Meeting, Minneapolis, MN, November 5, 1994. "Population-based outcomes measurement in surgery."
8. 58th International Mayo Alumni Meeting, San Diego, CA, March 25, 1995. "Breast Implants and Connective Tissue Disease: The Continuing Controversy."
9. Bertha Rosenstadt Visiting Professor, University of Toronto, Toronto, Ontario, Canada, April 5-7, 1995. "The Breast Implant Controversy: The Science, the Media, and the Law.”
10. Winona State University-Mayo Lecture Series, Winona, MN, April 11, 1995. "The Mayo Breast Implant Study: An Overview."
11. Women in Medicine: Personal Growth and Professional Development. Mayo Continuing Education, April 21, 1995. "Breast Implants and Connective Tissue Disease: The Continuing Controversy.”
12. Arthritis Foundation, Minnesota Chapter, Rheumatology Today Symposium, Arrowwood Resort, Alexandria, Minnesota, September 29-October 1, 1995. “Rheumatologists: Most Cost Effective Care Providers?”
13. Mayo Staff Meeting, Kahler Hotel, February 5, 1997, “From Cloning Genes to Statistical Means.”
14. Rotary II Club, Rochester Chapter, Rochester, MN, April 30, 1997 “Medical Research at Mayo: One Scientist’s Perspective.”
15. Highlights in Medicine, Royal University Hospital, Saskatoon, Canada, June 26-27, 1997. “The Breast Implant Controversy: A Complex Interplay between Science and the Law.”
16. University of Saskatchewan, Department of Rheumatology, Saskatoon, Canada, June 25, 1997. “Outcomes in Rheumatoid Arthritis.”
17. Arthritis Foundation, Minnesota Chapter Board of Directors Meeting, Mayo Foundation, Rochester, MN, September 20, 1997. “Population Research in Rheumatology.”
18. Rheumatology Grand Rounds, University of North Carolina, Chapel Hill, North Carolina, June 8, 1998. “Mortality in Rheumatoid Arthritis: Are We Making an Impact?”
19. Arthritis Foundation Grant Forum, 62nd National Scientific Meeting of the American College of Rheumatology, San Diego, CA, November 13, 1998. “Consequences of Arthritis Comorbidity with Aging.”
20. American College of Rheumatology Winter Rheumatology Symposium, Snowmass, CO, January 30-Feburary 5, 1999. “Giant Cell Arteritis: Can Epidemiology Provide Clues to Etiology?” and “Mortality in Rheumatoid Arthritis: Are We Making a Difference?”
21. Gender, Biology, and Human Disease Workshop, Hospital for Special Surgery, New York, NY, March 12-13, 1999. “Epidemiology of Gender-Discrepant Illness.”
22. Inaugural address, V International Symposium of Inflammation and the Rheumatic Diseases, Avila, Spain, April

15-16, 1999. “Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)” and “Mortality in Rheumatoid Arthritis: Are We Making a Difference?”

1. XXVIII Mexican Congress of Rheumatology, Leon Mexico, February 13-16, 2000. “Mortality in Rheumatoid Arthritis: Are we Making a Difference” and “Epidemiology of the Rheumatic Diseases.”
2. Meeting of the Spanish Society of Rheumatology, Santiago de Compostela, Spain, June 1-4, 2000. “Economic Evaluation in the Rheumatic Diseases.”
3. Oakbrook Terrace Illinois Development Event, Oakbrook Terrace, IL, June 26, 2000, “Research at Mayo Clinic Rochester.”
4. 64th National Scientific Meeting of the American College of Rheumatology, October 28-November 3, 2000, Philadelphia, PA, “Economic Evaluation in the Rheumatic Diseases.”
5. Department of Rheumatology Grand Rounds, University of Alabama, Birmingham, AL, December 13, 2000 “Is rheumatoid arthritis care more costly when provided by rheumatologists compared to generalists?”
6. Department of Medicine Grand Rounds, University of Alabama, Birmingham, AL, December 14, 2000 “Heart Disease in Rheumatoid Arthritis.”
7. Department of Rheumatology Grand Rounds, University of Illinois, Chicago, IL, January 31, 2001 “Heart Disease in Rheumatoid Arthritis.”
8. Merck-Immune Based Disease Franchise Consultants Meeting, April 25, 2001, Newark, NJ. “Trends in the Incidence and Mortality of Rheumatoid Arthritis in Rochester, MN over a 40-year Period.”
9. New Perspectives in Health Care and Management: The Mayo Case -- A Symposium at the American Academy in Berlin, Germany, May 8, 2001. “Mayo Clinic’s Vision of Research for the Early Portion of the 21st Century.”
10. American Society for Microbiology 101st General Meeting, Orlando, FL, May 23, 2001, “Sex Differences in the Rheumatic Diseases.”
11. American College of Rheumatology RA Database/R-24 Grant Meeting, Denver, CO, June 1, 2001, “Inclusion of Population-Based and other Reference Groups for Rheumatoid Arthritis” and “Pharmacoeconomics of Rheumatoid Arthritis - What do We Need to Know?”
12. Medical Grand Rounds, Mayo Clinic Scottsdale, AZ, August 24, 2001, “Heart Disease in Rheumatoid Arthritis.”
13. American Physiological Society, Genome and Hormones: An Integrative Approach to Gender Differences in Physiology, Pittsburgh, PA, October 20, 2001, “The Epidemiology of Gender Discrepant Illness.”
14. American College of Rheumatology 65th Annual Scientific Meeting, San Francisco, CA, November 10-15, 2001, “Mortality of Rheumatoid Arthritis in Rochester, MN, 1955-1994.”
15. Cedars Sinai Medical Center Grand Rounds, Los Angeles, CA. December 19, 2001. “Trends in the Incidence and Mortality of Rheumatoid Arthritis in Rochester, MN over a 40 year period.”
16. Medical Grand Rounds, University of Connecticut Health Center, Farmington, CT, January 16, 2002. “Trends in the Incidence and Mortality of Rheumatoid Arthritis in Rochester, MN over a 40 year period.”
17. Baylor College of Medicine CSTP Annual Retreat, Houston, TX. February 27, 2002. “The Mayo Clinical Research Training Program.”
18. 2nd International Conference on Giant Cell Arteritis and Polymyalgia Rheumatica, Mayo Clinic Rochester, August 22-25, 2002. “Epidemiology of Giant Cell Arteritis.”
19. American College of Rheumatology 66th Annual Scientific Meeting-ARHP Grant Forum, New Orleans, LA, October 25-29, 2002. “Cost and Quality Consequences of Rheumatologist vs. Non-Rheumatologist Care for Patients with Polymyalgia Rheumatica.”
20. Rheumatology Grand Rounds, Emory University, Atlanta, GA, February 12, 2003. “Trends in the Incidence and Mortality of Rheumatoid Arthritis in Rochester, MN over a 40-year Period.”
21. Medical Grand Rounds, Emory University, Atlanta, GA, February 11, 2003. “Infection in patients with rheumatoid arthritis.”
22. European League against Rheumatism, 2003 Annual European Congress of Rheumatology. Lisbon, Portugal, June 18-21, 2003. “The Value of Rheumatologists’ Care.”
23. American College of Rheumatology 67th Annual Scientific Meeting – Symposium: Novel Risk Factors for Cardiovascular Disease in Rheumatoid Arthritis. Orlando, FL, October 24-28, 2003. “Heart Disease in Rheumatoid Arthritis.”
24. Mayo Continuing Medical Education Course, Selected Topics in Rheumatology, Santa Ana Pueblo, NM, August 16, 2004, “Coronary Artery Disease in Rheumatoid Arthritis.”
25. American College of Rheumatology 68th Annual Scientific Meeting, San Antonio, TX, October 16-24, 2004, “Understanding the Impact of Comorbid Conditions in Rheumatoid Arthritis; different Incidence, prevalence, effect or the three?”
26. American College of Rheumatology 68th Annual Scientific Meeting, San Antonio, TX, October 16-24, 2004, “Increased unrecognized coronary heart disease in rheumatoid arthritis: a population-based cohort study.”
27. 56th Anniversary of the Portuguese Institute of Rheumatology, Lisbon, Portugal, December 10 &11, 2004, “Heart Disease in Rheumatoid Arthritis,” and, “Role of Risk Factors and Comorbidities in Heart Disease in Rheumatoid Arthritis.”
28. DC Rheumatism Society, Washington, DC, March 16-17, 2005, “Heart Disease in Rheumatoid Arthritis.”
29. AMGEN, Thousand Oaks, CA, July 8, 2005, “Heart Disease in Rheumatoid Arthritis.”
30. Heart Failure Society, Boca Raton, FL, September 18-21, 2005, “Heart Failure in Rheumatoid Arthritis.”
31. Minneapolis VA, Minneapolis, MN, September 30, 2005, “Heart Disease in Rheumatoid Arthritis” and “Mayo Clinic’s Clinical Research Scholars Program.”
32. Irish Society for Rheumatology, Dublin, Ireland, October 11-15, 2005, “Heart Disease in Rheumatoid Arthritis” and “The Epidemiology of Rheumatoid Arthritis.”
33. American College of Rheumatology 69th Annual Scientific Meeting, San Diego, CA, November 11-17, 2005, “ACR Committee on Quality Measures.”
34. Canadian Consensus Conference of Systemic Autoimmune Rheumatic Disease, Toronto, Canada, December 3-4, 2005, “Facts and Numbers - The Epidemiology of Systemic Autoimmune Rheumatic Disease.”
35. Hospital for Special Surgery, Distinguished Lecture Series, New York, New York, January 19-20, 2006, “Heart Disease in Rheumatoid Arthritis.”
36. Brigham and Women’s Hospital Grand Rounds, Boston, Massachusetts, February 2-7, 2006, “Heart Disease in Rheumatoid Arthritis.”
37. 24th Carl M. Pearson Memorial Symposium, Frontiers of Rheumatology, Santa Ana, CA, April 28-30, 2006, “Cardiovascular Disease in RA: Is there still a role for NSAIDS?” and “Cardiovascular Disease in RA: Can Tight Control Decrease Adverse Outcomes?”
38. Conference on Career Advancement for Women, Mayo Clinic Rochester, MN, June 5-6, 2006, “Academic Advancement.”
39. Orgryzlo Day, University of Toronto, Toronto, Ontario, June 12-14, 2006, “Heart Disease in Rheumatoid Arthritis.”
40. Spondyloarthritis Treatment and Research Network (SPARTAN), San Francisco, CA, July 28-30, 2006, “Future: Methods and Current Research for Prevalence.”
41. University of Puerto Rico, San Juan, Puerto Rico, August 23, 2006, “Clinical Research Training and Career Development: The Mayo Clinic Experience.”
42. GREAT Group Annual Meeting, October 7, 2006, Tucson, AZ, “Preparing Scientists to Work at the New Interfaces: Clinical Research Training and Career Development at Mayo.”
43. AAMC Annual Meeting, October 29, 2006, Seattle, WA, "Beyond CTSAs: Creating an Academic Home for Clinical & Translational Research: The Mayo Clinic Experience.”
44. ACR 70th Annual Meeting, November 11-15, 2006, Washington, DC, “ACR Committee on Quality Measures.”
45. Amgen-Wyeth, New York, New York, December 2, 2006, “Heart Disease in Rheumatoid Arthritis.”
46. University of Texas Health Science Center at Houston, Division of Rheumatology Grand Rounds, Thursday, April 18, 2007. “Heart Disease and Rheumatoid Arthritis.”
47. University of Nebraska Internal Medicine Grand Rounds, April 27, 2007. “Influence of Disease Comorbidity in Rheumatoid Arthritis.”
48. University of Minnesota, Upper Midwest Consortium, Multidisciplinary Clinical Research Conference, July 25-26, 2007. “Successful Investigators Panel.”
49. National Center for Research Resources Council, Bethesda, MD, September 11, 2007. “CTSA Education Steering Committee Update.”
50. Epstein Endowed Visiting Professor, University of California, San Francisco, December 3-4, 2007, “Heart Disease in Rheumatoid Arthritis.”
51. ACR Winter Rheumatology Symposium, Snowmass, CO, January 27, 2008, “New Insights into the Epidemiology of Rheumatoid Arthritis”
52. ACR Winter Rheumatology Symposium, Snowmass, CO, January 28, 2008, “Heart Disease in Rheumatoid Arthritis”
53. Samsung Medical Center, Seoul, Korea, Medical Grand Rounds, March 5, 2008, “Heart Disease in Rheumatoid Arthritis.”
54. Advances in Targeted Therapies, Rapallo, Liguria, Italy, April 2, 2008, “Why do patients with Rheumatoid Arthritis Still Die Prematurely?”
55. Upper Midwest Clinical and Translational Science Consortium Meeting, Rochester, Minnesota, June 17-18, 2008, “Building a Regional Clinical & Translational Science Consortium.”
56. University of Texas Health Science Center at Houston, Division of Rheumatology Grand Rounds, December 18, 2008, Houston, Texas. “Heart Disease in Rheumatoid Arthritis.”
57. Women in Government 15th Annual State Directors Conference, January 3, 2009, St. Petersburg, Florida, “Rheumatoid Arthritis in Women.”
58. 11th Annual Advances in Targeted Therapy conference, April 23, 2009, Mandelieu, France. “Heart Disease in RA: Can we reduce the risk?”
59. European League Against Rheumatism (EULAR), June 12, 2009, Copenhagen, Denmark. “Mortality and Co- Morbidity in Rheumatoid Arthritis and Impact of Biologics.”
60. The National Professional Healthcare Standardisation Programme, June 16, 2009, Prague Czech Republic. “Quality: The Mayo Clinic Approach.”
61. MMI Clinician Scientist Fellows Annual Meeting, July 11, 2009, Galway, Ireland. “Heart Disease and Premature Death in RA: Lessons from Epidemiology”
62. University of Massachusetts Medical Grand Rounds, November 12, 2009, Boston, MA. “Heart Disease in Rheumatoid Arthritis.”
63. Cedars-Sinai Medical Grand Rounds, January 27, 2010, Los Angeles, CA. “Heart Disease in Rheumatoid Arthritis - New Insights.”
64. National Center for Research Resources: CTSA Industry Forum: *Promoting Efficient and effective Collaborations Among Academic, Government and Industry. “*Educational Curricula in Translational Research: Opportunities Among CTSAs, NIH and Industry, February 17-18, 2010, Bethesda Maryland.
65. Institute of Medicine of the National Academies, “The Learning Healthcare System in 2010 and Beyond: *Understanding, Engaging and Communicating the Possibilities*. “Health Systems as research platforms – enhancing science, value and innovation.” April 1-2, 2010, Washington DC
66. Perspectives in Rheumatic Diseases 2010 Conference presented by *Rheumatology News, Family Practice News, and Internal Medicine News,* October 22, 2010, Santa Monica, CA. “Cardiovascular Issues and the Rheumatoid Arthritis Patient.”
67. Post-EULAR Cardiovascular Risk Management Conference. “Towards better Cardiovascular Risk Prediction in RA”, January 19-23, 2011, Amsterdam, Netherlands.
68. Canadian Rheumatology Association, February 12, 2011, Cancun, Mexico. “Heart Disease in Rheumatoid Arthritis.”
69. National Society of Clinical Rheumatologists, April 1-3, 2011, Monterey, CA. “Heart Disease and the Rheumatoid Arthritis Patient.”
70. First International Rheumatology and Cardiology Focus on: *Inflammation, a Shared Concern*. “Risk of Cardiovascular Events in Rheumatoid Arthritis”, June 9-11, 2011, Prato, Italy.
71. Institute of Medicine of the National Academies, *Roundtable on Value and Science-Driven Healthcare*, Clinical Effectiveness Research Innovation Collaborative, “The Patient Centered Outcomes Research Institute & Methodology Committee”, July 25, 2011, Washington, DC.
72. Texas Health Research & Education Institute, Internal Medicine & Rheumatology Grand Rounds, “Heart Disease and the Rheumatoid Arthritis Patient”, August 24, 2011, Dallas TX.
73. Mayo Clinic Alumni, 67th Meeting: *Innovation into Action*, “The Mayo Clinic Office of Business Development & Strategic Alliances”, September 21-24, 2011, Jacksonville, FL.
74. The U.S. Bone & Joint Initiative, *Value in Musculoskeletal Care,* “The Role of Population Health Research in Defining Value in Musculoskeletal Care”, October 12-13, 2011, Washington, DC.
75. Institute of Medicine of the National Academies, *Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020,* Session Chair and Discussant for “Developing a Robust Clinical Trials Workforce”, November 7-8, 2011, Washington, DC.
76. University of Colorado, *Rheumatology Research Seminar,* “Heart Disease and the RA Patient”, December 6, 2011, Denver, Colorado.
77. Kaiser Permanente Southern California, *Department of Research & Evaluation*, “Patient-Centered Outcomes Research Institute and PCORI Methodology Committee”, December 19, 2011, Pasadena, CA.
78. Hospital for Special Surgery, “Enhancing Value: in Musculoskeletal Care: The Strategic Role of Outcomes Research”. January 13, 2012, New York, New York.
79. MD Anderson Cancer Center, “The Patient Centered Outcomes Research Institute, Insights from an Insider”, February 10, 2012, Houston, Texas.
80. Drug Information Association National Meeting (DIA, “Heterogeneity of Treatment Effects, Estimating Risk of Harm in the context of Comorbidity: Biologics & Rheumatoid Arthritis.” March 15, 2012, Washington, DC.
81. Translational Science 2012, Improving Health Through Research and Training, “The Patient-Centered Outcomes Research Institute & PCORI Methodology Committee.” April 18, 2012, Washington, DC.
82. EULAR, Outcomes Sciences: Equity Issues in Rheumatology, “How could we reduce inequities?” June 7, 2012, Berlin, Germany.
83. DEcIDE Methods Symposium, “The PCORI Methods Report: what it means for future CER methods development”. June 12, 2012, Rockville, MD.
84. Royal University Hospital Rheumatology Grand Rounds, “Strain Echocardiography for Evaluation of Myocardial Function in Rheumatoid Arthritis”. June 26, 2012, Saskatchewan, Canada.
85. Royal University Hospital Department of Medicine Grand Rounds, Donald Mitchell Memorial Lectureship, “Cardiovascular Risk in Rheumatoid Arthritis Patient”. June 27, 2012, Saskatchewan, Canada.
86. University of Alabama Birmingham, Rheumatology Grand Rounds, “Cardiovascular Risk in Rheumatoid Arthritis Patients.” September 13, 2012 Birmingham, Alabama.
87. Association of American Medical Colleges, National Meeting, “Integrating Research with Practice to Advance Science & Improve Health: The Critical role of Training & Career Development,” September 21, 2012, Nashville, Tennessee.
88. American College of Rheumatology (ACR), Round Table Discussion, “Setting Priorities for Future Actions,” November 10, 2012, Washington, DC.
89. Town Hall Meeting, “Faculty Development Workshop,” December 11, 2012, Mayo Medical School, Rochester, MN.
90. Arizona Leadership Council, “Mayo Medical School Educating Physician Leaders in: Patient Centered, Science Driven, Team Based, High Value Health Care To heal patients and the healthcare system.” March 22, 2013, Mayo Medical School, Scottsdale, AZ.
91. Mayo Foundation Chapter of Sigma Xi, “A New Vision for Mayo Medical School To heal patients and the healthcare system,” April 16, 2013, Mayo Medical School, Rochester, MN
92. Regional Premed Advisor’s Conference, “A New Vision for Mayo Medical School,” April 26, 2013, Mayo Medical School, Rochester, MN
93. Mayo Medical School RETREAT, “One School, Three + sites,” May 16, 2013, Rochester, MN.
94. Mayo Clinic Board of Governors, *“National Medical School*,” August 7, 2013, Mayo Medical School, Rochester, MN.
95. Mayo Clinic Health System Education Committee, “Transforming Medical Education through the Science of Health Care Delivery,” August 12, 2013, Mayo Medical School, Rochester, MN
96. Grand Rounds, “Vision for a National Medical School,” September 11, 2013, Mayo Medical School, Jacksonville, FL.
97. MMS Faculty Town Hall “Mayo Medical School Creating a national presence for medical education across Mayo Clinic,” September 17, 2013, Rochester, MN.
98. Immersion Journey, “Mayo Medical School The Next Generation of Health Care Leaders,” September 18, 2013, Mayo Medical School, Rochester, MN.
99. Mayo Clinic Arizona Education Committee, “Creating a national presence for medical education across Mayo Clinic,” September 26, 2013, Mayo Medical School, Arizona, MN.
100. Executive Operating Team Presentation. November *“Leveraging Mayo Clinic’s footprint to create a school with national impact & brand,”* November 13, 2013, Mayo Medical School, Rochester, MN.
101. Arthritis and Rheumatism (ACR), “Application of a novel measure of socioeconomic status using individual housing data in rheumatology research,” October 28, 2013, San Diego, CA.
102. Association of American Medical Colleges (AAMC), Implementation Science Symposium, “Medical Education in Implementation Science Across the Continuum of Learners,” November 3, 2013, Philadelphia, PA.
103. 10th Anniversary Summit, “Patient Centered Outcomes Research as an Effective Model to Improve Health Care and Dissemination of Research Results,” February 27, 2014, San Juan, Puerto Rico.
104. Advances in Targeted Therapies, “Comorbidities in RA: have they changed in the past decade?” March 27, 2014, Athens, Greece.
105. 32nd Carl M. Pearson Memorial Symposium Frontiers of Rheumatology, “Managing CV Risk in the Rheumatoid Arthritis Patient,” April 4, 2014, Marina del Rey, CA.
106. 4th Annual Texas State Rheumatology Round-Up Conference, “Heart Disease in the Rheumatoid Arthritis Patient,” April 12, 2014, Dallas, TX.
107. National Society for Clinical Rheumatology Annual Meeting, “Enhancing Value in Musculoskeletal Care: Best Care at Lower Cost,” May 2, 2014, Asheville, NC.
108. Master’s Series, Genentech Medical Affairs, “Epidemiology of Cardiovascular Disease in Rheumatoid Arthritis,” July 14, 2014, San Francisco, CA
109. Master’s Series, Genentech Medical Affairs, “Cardiovascular Risk Assessment in Rheumatoid Arthritis Patients,” July 14, 2014, San Francisco, CA
110. Cedar Sinai Rheumatology Grand Rounds, “Insights from studies of Heart Disease in Rheumatoid Arthritis,” July 23, 2014, Los Angeles, CA
111. 7th Annual Perspectives in Rheumatic Disease, “Cardiovascular Co-morbidities in Rheumatic Diseases: Who Should Care, Why & What to Do,” September 12, 2014, Las Vegas, Nevada
112. Arthritis Unmasked: Genetics, Treatments and Partnerships 2nd Arthritis Alliance Conference and Research Symposium, “Heart Disease and the RA Patient…The evolution of observation,” October 30, 2014, Toronto, Canada. ***Presented in partnership with Gairdner Foundation and CIHR’s Institute of Musculoskeletal Health and Arthritis.***
113. ACR National Meeting, Clinical Research Pre-Conference, “PCORI Methodology Committee: Why Methods Matter,” November 14, 2014, Boston, MA
114. ACR National Meeting, Clinical Symposium, “Epidemiology of CVD in Patients with Rheumatoid Arthritis,” November 18, 2014, Boston, MA
115. Global Cardiovascular Advisory Board, “The Impact of Rheumatoid Arthritis Disease Activity (Flare and Cumulative Burden) on Cardiovascular Disease Risk,” December 10, 2014, Boston, MA
116. Medicine Grand Rounds at the Dartmouth-Hitchcock Medical Center, “Heart Disease & the RA Patient, the evolution of observation,” December 12,2014, Lebanon, New Hampshire
117. Translation Science 2015, “Emerging Domains in Translation Science,” April 18, 2015, Washington, DC
118. Alumni Association 97th Annual Meeting, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, October 22, 2015, Hospital for Special Surgery, New York
119. Alumni Association 97th Annual Meeting, “Defining Value in MSK Care in the Context of Emerging New Models in Healthcare Delivery”, October 23, 2016, Hospital for Special Surgery, New York
120. Medicine Grand Rounds, Rutgers Robert Wood Johnson Medical School, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, November 4, 2015, New Brunswick, New Jersey
121. Inaugural Grand Rounds for the Institute for Excellence in Education, Rutgers Robert Wood Johnson Medical School, “The Science of Health Care Delivery”, January 11, 2016, New Brunswick, New Jersey
122. Grand Rounds, Department of Population Health Science and Policy, Icahn School of Medicine Mount Sinai, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, January 12, 2016, New York
123. Lecture Series, The Princeton Adult School, “The Transformation of Medical Education in America”, March 29, 2016, Princeton, New Jersey
124. AWARE (Advancing Women Through Advocacy, Recognition and Empowerment) Program, Robert Wood Johnson University Hospital, “Personal Perspectives on my Career in Medicine”, March 30, 3016, New Brunswick, New Jersey
125. Medical Grand Rounds, St. Peter’s University Medical Center, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, April 19, 2016, New Brunswick, New Jersey
126. Inaugural Grand Rounds for the Institute for Excellence in Education, Rutgers Robert Wood Johnson Medical School, “The Science of Health Care Delivery”, January 11, 2016, New Brunswick, New Jersey
127. Grand Rounds, Department of Population Health Science and Policy, Icahn School of Medicine Mount Sinai, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, January 12, 2016, New York
128. Lecture Series, The Princeton Adult School, “The Transformation of Medical Education in America”, March 29, 2016, Princeton, New Jersey
129. AWARE (Advancing Women Through Advocacy, Recognition and Empowerment) Program, Robert Wood Johnson University Hospital, “Personal Perspectives on my Career in Medicine”, March 30, 3016, New Brunswick, New Jersey
130. Medical Grand Rounds, St. Peter’s University Medical Center, “Heart Disease in Rheumatoid Arthritis: The Evolution of an Observation”, April 19, 2016, New Brunswick, New Jersey
131. Seminar Speaker, Rutgers Robert Wood Johnson Medical School Retired Faculty Association, “RWJMS – The State of the School”, May 5, 2016, Piscataway, New Jersey
132. Symposium Speaker, Stuart D. Cook Master Educator’s Guild Spring Symposium, “A Vision for Quality and Safety at RWJMS”, May 11, 2016, RWJMS, New Brunswick, New Jersey
133. Symposium Speaker, First Annual Medical Student Research Symposium, “Personal Perspectives on Developing a Clinical Research Career”, August 10, 2016, RWJMS, Piscataway, New Jersey
134. Invited Speaker, New Jersey Rheumatology Association, “Heart Disease and the Rheumatoid Arthritis Patient”, November 2, 2016, West Orange, New Jersey
135. 2016 ACR/ARHP Annual Meeting, “Cardiovascular Outcomes in Rheumatoid Arthritis…the evolution of observation”, November 15, 2016, Washington, DC
136. Medical Grand Rounds speaker, “My Professional Journey in Academic Medicine”, February 1, 2017, University of Miami, Florida
137. Rush University Internal Medicine Grand Rounds & Rheumatology Grand Rounds. “Cardiovascular Outcomes in Rheumatoid Arthritis”, April 26-27, 2017, Chicago, Illinois.

# MEDIA *(selected citations only)*

1. *ModernPhysician*, **Mayo Medical School names Gabriel Dean, by Joe Carlson**. November 2012.
2. *Post Bulletin*, **Mayo Medical School students rock Match Day by Jeff Hansel**, March 2013.
3. *FierceHealthcare,* **Are 3-year medical degrees good enough for future docs? By Alicia Caramenico**, September 2013.
4. *MedPage Today,* **The 3 Year Medical School: Is Shorter Good Enough? By Ben Hartman, M.D**., September 2013.
5. *Hospitals and Health Networks,* **Mayo Med School Works to Transform Doc Education by Paul Barr**, describes the future for medical education. December 2013.
6. *Minnesota Medicine,* **Ten at the Top by Carmen Peoto**, March 10, 2014.
7. *Commonwealth Fund*, In Focus: Modernizing Medical Education to Advance New Care Models and Foster Continuous Quality Improvement Encouraging High-Quality, Value-Based Care by Martha Hostetter, April/May 2014.
8. *MedpageToday*, **New Tool Will Pinpoint CVD Risk in Arthritis,** June 18, 2014.
9. *PolitcoPro*, **Fixing medical education: Schools look for new models**, January 2, 2015.
10. *Wall Street Journal*, **Innovation is Sweeping through U.S. Medical Schools,** February 16, 2015.
11. *Patch.com,* **Mayo Medical School Dean Hired For Top Post At Rutgers Medical**, April 6, 2015.
12. *Science Daily*, **Rheumatoid arthritis and giant cell arteritis linked with solar cycles,** June 15, 2015.
13. *MyCentralJersey.com*, **A look at recent Central Jersey hires, promotions**, June 19, 2015.
14. *MyCentralJersey.com*, **New dean welcomes Rutgers med school’s largest class**, August 8, 2015.
15. [*www.innovationnj.net,*](http://www.innovationnj.net/) **New dean welcomes Rutgers medic school’s largest class**, August 18, 2015.
16. *Pallone.house.gov>Newsroom*, **Pallone Hosts Discussion with Public Health Experts to Highlight Zika**, February 23, 2016.
17. *Bel Marra Health*, **Rheumatoid arthritis and giant cell arteritis linked with solar cycles**, February 24, 2016.
18. *MyCentralJersey.com*, **Med School Match Day in New Brunswick**, March 18, 2016
19. [*www.njha.com*,](http://www.njha.com/) **Healthcare Leaders Honored at Executive Women Gala**, May 10, 2016
20. [*www.rwjbhinfo.org*,](http://www.rwjbhinfo.org/) **Executive Women of NJ To Honor 11 Executive Women from**, May 4, 2016
21. *MyCentralJersey.com*, **Heartbeats: Saint Peter’s earns an ‘A’ grade**, May 9, 2016
22. *India-herald.com*, **Woman is a powerful force that can move everything**, July 6, 2016
23. *MyCentralJersey.com*, **Rutgers holds annual White Coat Ceremony for first-year med students**, August 5, 2016

**BIBLIOGRAPHY *(h Index = 93 Scopus® 2022)***

# Peer-reviewed manuscripts published or in press (\*primary mentor for first author)

1. **Gabriel SE**, Conn DL, Phyliky RL, Pittelkow MR, Scott RE. Vasculitis in hairy cell leukemia: Review of literature and consideration of possible pathogenic mechanisms. *J Rheumatol* 1986;13(6):1167-72.
2. **Gabriel SE**, Luthra HS. Rheumatoid arthritis: Can the long-term outcome be altered? *Mayo Clin Proc*

1988;63:58-68.

1. **Gabriel SE**, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: A scleroderma-like disorder with systemic manifestations. *Medicine* 1988;67(1):58-65.
2. Machado EBV, **Gabriel SE**, Beard CM, Michet CJ, O'Fallon WM, Ballard DJ. A population-based case-control study of temporal arteritis: Evidence for an association between temporal arteritis and degenerative vascular disease? *Int J Epidemiol* 1989;18(4):836-41.
3. **Gabriel SE**, Bombardier C. Clinical trials in fibrositis: A critical review and future directions. *J Rheumatol*

1989;16(Suppl 19):177-9.

1. **Gabriel SE**, Bombardier C, Jaakkimainen L. Examining the risks for NSAID-induced gastropathy. *Can J Gastroenterol* 1990;4(3):108-12.
2. **Gabriel SE**, Conn DL, Luthra H. Rifampin therapy in rheumatoid arthritis. *J Rheumatol* 1990;17(2):163-6.
3. **Gabriel SE**, Creagan E, O'Fallon WM, Jaquith J, Bunch T. Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. *J Rheumatol* 1990;17(4):460-5.
4. **Gabriel SE**, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. *Ann Internal Med* 1991;115(10):787-96.
5. **Gabriel SE**, Fehring RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990. *J Clin Epidemiol* 1992;45(9):1041-4.
6. **Gabriel SE**, Jaakkimainen RL, Bombardier C. Cost effectiveness of misoprostol for nonsteroidal anti- inflammatory drug-associated adverse gastrointestinal events. *Focus Rheumatol* 1994;1(1):21-2.
7. **Gabriel SE**, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis (RA) patients receiving nonsteroidal anti-inflammatory drugs (NSAID). *Arthritis Rheum* 1994;37(3):333- 41.
8. \*Achkar AA, Lie JT, Hunder GG, O'Fallon WM, **Gabriel SE**. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? *Ann Internal Med* 1994;120(12):987-92.
9. **Gabriel SE**. The sensitivity and specificity of computerized data bases for the diagnosis of rheumatoid arthritis.

*Arthritis Rheum* 1994;37(6):821-3.

1. **Gabriel SE**, O’Fallon WM, Kurland LT, Beard CM, Woods JE, Melton LJ III. Risk of connective tissue diseases and other disorders after breast implantation. *N Engl J Med* 1994;330(24):1697-1702.
2. **Gabriel SE**, Wenger DE, Ilstrup DM, Lewallen DG, Melton LJ III. Lack of evidence for gender bias in the utilization of total hip arthroplasty among Olmsted County, Minnesota residents with osteoarthritis. *Arthritis Rheum* 1994;37(8)1171-6.
3. \*Salvarani C, **Gabriel SE**, Gertz MA, Bjornsson J, Li C-Y, Hunder GG. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. *Arthritis Rheum* 1994;37:1621-6.
4. **Gabriel SE,** Crowson CS, Campion ME, O’Fallon WM. Is prescription medication use a useful measure of comborbidity? Pharmacoepidemiology and Drug Safety. 1995; 4(Suppl 1):S84.
5. **Gabriel SE**, O'Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. *J Rheumatol* 1995;22:93-6.
6. \*Salvarani C, **Gabriel SE**, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatic in Olmsted County, Minnesota, 1970-1991. *Arthritis Rheum* 1995;38(3):369-73.
7. **Gabriel SE**, O'Fallon WM, Beard CM, Kurland LT, Woods JE, Melton LJ III. Trends in the utilization of silicone breast implants, 1964-1991, and methodology for a population-based study of outcomes. *J Clin Epidemiol* 1995;48(4):527-37.
8. **Gabriel SE**, Crowson CS, O'Fallon WM. Costs of osteoarthritis: estimates from a geographically-defined population. *J Rheumatol* 1995;22(Suppl 43):23-5.
9. **Gabriel SE**. Economic evaluation using mathematical models: the case of misoprostol prophylaxis. *J Rheumatol*

1995;22:1412-4.

1. \*Salvarani C, **Gabriel SE**, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota, apparent fluctuations in a cyclic pattern. *Ann Internal Med* 1995;123:192-4.
2. **Gabriel SE**, EL Matteson. Economic and Quality-of-Life Impact of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. *Pharmacoeconomics* 1995;8:479-90.
3. \*Achkar AA, Lie JT, **Gabriel SE**, Hunder GG. Giant cell arteritis involving the facial artery. *J Rheumatol*

1995;22:360-2.

1. **Gabriel SE**. Has the cost-effectiveness of misoprostol been underestimated? *Arch Intern Med* 1995;155: 1448-51.
2. Esdaile JM, Liang MH, Clarke AE, Condit JM, Fortin PR, **Gabriel SE**, Natz JN, Partridge AJ, Prashker M, Ward MM. Role of specialty care for chronic disease. *Mayo Clin Proc* 1996;71:1179-81.
3. \*Peterson LS, Nelson AM, Su WPD, Mason T, O’Fallon WM, **Gabriel SE**. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. *J Rheumatol* 1997;24:73-80.
4. **Gabriel SE**, Crowson CS, Campion ME, O'Fallon WM. Indirect and non-medical costs among people with RA and OA compared with nonarthritic controls. *J Rheumatol* 1997;24:43-8.
5. **Gabriel SE.** Epidemiology and health services research. *Curr Opin Rheumatol* 1997;9(2):87-132
6. **Gabriel SE**, Wagner JL. Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects. *Arthritis Care Res* 1997;10(1):56-63.
7. **Gabriel SE,** Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ. Complications leading to surgery after breast implantation. N Engl J Med 1997;336(10):677-82.
8. **Gabriel SE**, Crowson CS, Campion ME, O’Fallon WM. Direct medical costs unique to people with arthritis. *J Rheumatol* 1997;24:719-25.
9. **Gabriel SE**, Amadio PC, Ilstrup D. The feasibility and validity of studies comparing orthopedists and non- orthopedists caring for musculoskeletal injuries: results of a pilot study. *Arthritis Care Res* 1997;10(3):163-8.
10. **Gabriel SE**, Sunku J, Salvarani C, O’Fallon WM, Hunder G. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. *Arthritis Rheum* 1997;40(10):1873-8.
11. \*Peterson LS, Mason T, Nelson AM, O’Fallon, WM, **Gabriel SE**. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled population-based study. *Arthritis Rheum* 1997;40(12):2235-40.
12. **Gabriel SE**. NSAIDs: Knowing the risk promotes safer use*. J Musculoskeletal Med* 1997;14(11):39-48.
13. \*Pasha T, **Gabriel S**, Therneau T, Dickson ER, Lindor K. Cost effectiveness of ultrasound guided liver biopsy.

*Hepatol* 1998;25(5):1220-6.

1. \*Farkouh ME, Smars PA, Reeder GS, Zinsmeister AR, Evans RW, Meloy TD, Kopecky SL, Allen M, Allison TG, Gibbons RJ, **Gabriel SE**. A clinical trial of a chest pain observation unit for patients with unstable angina. *N Engl J Med* 1998;339(26):1882-8.
2. \*Uramoto KM, Michet CJ Jr., Thumboo J, Sunku J, O’Fallon WM, **Gabriel SE**. Trends in the incidence and mortality of systemic lupus erythematosus (SLE) - 1950-1992. *Arthritis Rheum* 1999;42(1):46-50.
3. \*Heid, IM, O’Fallon JR, Schwenk NM, **Gabriel SE**. Increasing the proportion of women in academic medicine: One institution’s response. *Mayo Clin Proc* 1999;74(2)113-9.
4. \*Pasha T, Heathcote J, **Gabriel S**, Cauch-Dudek K, Jorgensen R, Therneau T, Dickson ER, Lindor KD. Cost- effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. *Hepatol* 1999;29:21-6.
5. **Gabriel SE**, Tugwell P, O’Brien B, Yelin E, Drummond M, Ruff B, Brooks P, Bombardier C. Report of the OMERACT Task Force on economic evaluation. *J Rheumatol* 1999;25:203-6.
6. **Gabriel SE**, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, MN 1955-1985.

*Arthritis Rheum* 1999;42(3):415-20.

1. **Gabriel SE**, Kneeland TS, Melton LJ III, Moncur MM, Ettinger B, Tosteson ANA. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? *Med Decis Making* 1999;19:141-8.
2. **Gabriel SE**, Crowson CS, Luthra HS, Wagner JL, O’Fallon WM. Modeling the lifetime costs of rheumatoid arthritis. *J Rheumatol* 1999;26:1269-74.
3. \*Caraballo P, **Gabriel SE**, Castro MR, Atkinson EJ, Melton LJ. Changes in bone density after exposure to oral anticoagulants: A meta-analysis. *Osteoporos Int* 1999;9:441-8.
4. \*Cuddihy M-T, **Gabriel SE**, Crowson CS, O'Fallon WM, Melton LJ, III. Forearm fractures as predictors of subsequent osteoporotic fractures. *Osteoporos Int* 1999;9:469-75.
5. \*Proven A, **Gabriel SE**, O’Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. *J Rheumatol* 1999;26:1333-7.
6. **Gabriel SE**, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. *Arthritis Rheum* 1999;42(6):1255-8.
7. **Gabriel SE**, Crowson CS, O’Fallon WM. A comparison of 2 comorbidity instruments in arthritis. *J Clin Epidemiol*

1999;52(12):1137-42.

1. **Gabriel SE**, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades?

*J Rheumatol* 1999;26(12):2529-33.

1. **Gabriel SE**. The epidemiology of gender-discrepant illness. *Lupus* 1999;8(5)339-45.
2. Lockshin MD, **Gabriel SE**, Zakeri Z, Lockshin RA. Gender, biology and human disease: report of a conference.

*Lupus* 1999;8(5):335-8.

1. \*Roger VL, Jacobsen SJ, Weston SA, **Gabriel SE**. Sex differences in the epidemiology and outcomes of heart disease: population-based trends. *Lupus* 1999;8(5)346-50.
2. **Gabriel SE**, Crowson CS, O’Fallon WM. Comorbidity in arthritis. *J Rheumatol* 1999;26(11):2475-9.
3. \*Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, **Gabriel SE**. The epidemiology of psoriatic arthritis in Olmsted County, 1982-1991. *J Rheumatol* 2000;27:1247-50.
4. \*Roger VL, Farkouh ME, Weston SA, Reeder GS, Jacobsen SJ, Zinsmeister AR, Yawn BP, Kopecky SL, **Gabriel SE**. Sex differences in the evaluation and outcome of unstable angina (UA): a population-based study. *JAMA* 2000;283:646-52.
5. Yawn BP, Amadio P, Harmsen WS, Hill J, Ilstrup D, **Gabriel SE**. Isolated acute knee injuries in the general population. *J Trauma* 2000;48(4):716-23.
6. Tosteson ANA, **Gabriel SE**, Kneeland TS, Moncur M, Manganiello PD, Schiff I, Ettinger B, Melton L Joseph III. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? *J Women's Health* 2000;9(2):119-30.
7. **Gabriel SE**, Kneeland TS, Melton LJ III, Moncur MM, Ettinger B, Tosteson ANA. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? *Med Decis Making* 1999;19:141-8.
8. \*Caraballo P, **Gabriel SE**, Castro MR, Atkinson EJ, Melton LJ. Changes in bone density after exposure to oral anticoagulants: A meta-analysis. *Osteoporos Int* 1999;9:441-8.
9. \*Cuddihy M-T, **Gabriel SE**, Crowson CS, O'Fallon WM, Melton LJ, III. Forearm fractures as predictors of subsequent osteoporotic fractures. *Osteoporos Int* 1999;9:469-75.
10. \*Proven A, **Gabriel SE**, O’Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. *J Rheumatol* 1999;26:1333-7.
11. **Gabriel SE**, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. *Arthritis Rheum* 1999;42(6):1255-8.
12. **Gabriel SE**, Crowson CS, O’Fallon WM. A comparison of 2 comorbidity instruments in arthritis. *J Clin Epidemiol*

1999;52(12):1137-42.

1. **Gabriel SE**, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades?

*J Rheumatol* 1999;26(12):2529-33.

1. **Gabriel SE**. The epidemiology of gender-discrepant illness. *Lupus* 1999;8(5)339-45.
2. Lockshin MD, **Gabriel SE**, Zakeri Z, Lockshin RA. Gender, biology and human disease: report of a conference.

*Lupus* 1999;8(5):335-8.

1. \*Roger VL, Jacobsen SJ, Weston SA, **Gabriel SE**. Sex differences in the epidemiology and outcomes of heart disease: population-based trends. *Lupus* 1999;8(5)346-50.
2. **Gabriel SE**, Crowson CS, O’Fallon WM. Comorbidity in arthritis. *J Rheumatol* 1999;26(11):2475-9.
3. \*Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, **Gabriel SE**. The epidemiology of psoriatic arthritis in Olmsted County, 1982-1991. *J Rheumatol* 2000;27:1247-50.
4. \*Roger VL, Farkouh ME, Weston SA, Reeder GS, Jacobsen SJ, Zinsmeister AR, Yawn BP, Kopecky SL, **Gabriel SE**. Sex differences in the evaluation and outcome of unstable angina (UA): a population-based study. *JAMA* 2000;283:646-52.
5. Yawn BP, Amadio P, Harmsen WS, Hill J, Ilstrup D, **Gabriel SE**. Isolated acute knee injuries in the general population. *J Trauma* 2000;48(4):716-23.
6. Tosteson ANA, **Gabriel SE**, Kneeland TS, Moncur M, Manganiello PD, Schiff I, Ettinger B, Melton L Joseph III. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? *J Women's Health* 2000;9(2):119-30.
7. **Gabriel SE**, Amadio PC, Ilstrup DM, Harmsen WS, Huschka TR, Hill JL, Yawn, BP. Change in diagnosis among orthopedists compared to non-orthopedists in the management of acute knee injuries. *J Rheumatol* 2000;27:2412- 17.
8. Allison TG, Farkouh ME, Smars PA, Evans RW, Squires RW, **Gabriel SE**, Kopecky SL, Gibbons RJ, Reeder GS. Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). *Am J Cardiol* 2000;86(2):133-8.
9. **Gabriel SE**, Drummond M, Coyle D, Suarez-Almazor ME, Ruff B, Guillemin F, Bombardier C, Boers M, Maetzel A, Ruof J, Cranney A, Marentette M, Tugwell P. OMERACT V - Economics Working Group: Summary, recommendations, and research agenda. *J Rheumatol* 2001;28(3):640-1.
10. Coyle D, Welch V, Shea B, **Gabriel S**, Drummond M, Tugwell P. Issues of consensus and debate for economic evaluation in rheumatology. *J Rheumatol* 2001;28(3):642-7.
11. \*French AR, Mason T, Nelson AM, O’Fallon WM, **Gabriel SE**. Increased mortality in adults with a history of juvenile rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2001;44(2):523-7.
12. **Gabriel SE**, Wagner JL, Zinsmeister AR, Scott CG, Luthra HS. Is rheumatoid arthritis (RA) care more costly when provided by rheumatologists compared to generalists? *Arthritis Rheum* 2001;44(7):1504-14.
13. **Gabriel SE**, Coyle D, Moreland LW. A clinical and economic review of disease modifying antirheumatic drugs.

*Pharmacoeconomics* 2001;19(7):715-28.

1. **Gabriel SE**. Epidemiology of rheumatoid arthritis. *Rheum Dis Clin N Am* 2001;27(2):269-81.
2. \*Bidaut-Russell M and **Gabriel SE**. Adverse gastrointestinal effects of NSAIDs: Consequences and costs.

*Baillière’s Clinical Gasteroenterol* 2001;15(5):739-53.

1. Woloshin S, Schwartz LM, Moncur M, **Gabriel SE**, Tosteson ANA. Assessing values for health: numeracy matters.

*J Med Decis Making* 2001;21:382-90.

1. \*Thumboo J, Uramoto K, O’Fallon WM, Fong KY, Boey ML, Feng PH, Thio ST, **Gabriel SE**, Chng HK, Howe, HS, Koh ET, Koh WH, Leong KH, Leong KP. A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, MN, and Chinese in Singapore, from 1980-1992. *Arthritis Care Res* 2001;45(6):494-500.
2. Tosteson ANA, **Gabriel SE**, Grove MR, Moncur MM, Kneeland TS, Melton LJ III. Impact of hip and vertebral fractures on quality adjusted life years. *Osteoporos Int.* 2001;12:1042-9.
3. Graham RR, Langefeld CD, Gaffney PM, Ortmann WA, Selby SA, Baechler EC, Shark KB, Ockenden TC, Rohlf KE, Moser KL, Brown WM, **Gabriel SE**, Messner RP, King RA, Horak P, Elder JT, Stuart PE, Rich SS, and Behrens TW. Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus. *Arthritis Res* 2001;3(5):299-305.
4. **Gabriel SE,** Drummond M, Suarez-Almazor ME, Ruff B. Guillemin F, Bombardier C, Boers M, Maetzel A, Ruof J, Cranney A, Marentette M, Tugwell P. OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. J Rheumatol. 2001 Mar;28(3):670-3.
5. Turesson C, O’Fallon WM, Crowson CS, **Gabriel SE**, Matteson EL. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. *J Rheumatol* 2002;29:62-7.
6. \*Doran MF, Pond GR, Crowson CS, O’Fallon WM, **Gabriel SE**. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota over a 40-year period. *Arthritis Rheum* 2002;46(3):625-31.
7. **Gabriel SE**, Tosteson ANA, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ III. Direct medical costs attributable to osteoporotic fractures. *Osteoporos Int* 2002;13:323-30.
8. Massardo L, **Gabriel SE**, Crowson CS, O’Fallon WM, Matteson EL. A population-based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. *J Rheumatol* 2002;29:52-6.
9. \*Cuddihy M-T, **Gabriel SE**, Crowson CS, Atkinson EJ, Tabini C, O'Fallon WM, Melton LJ, III. Osteoporosis interventions following distal forearm fracture: A missed opportunity. *Arch Intern Med* 2002;162(4):421-6.
10. \*French AR, Mason T, Nelson AM, Crowson CS, O’Fallon WM, Khosla S, **Gabriel SE**. Osteopenia in adults with a history of juvenile rheumatoid arthritis: a population-based study. *J Rheumatol* 2002;29(5):1065-70.
11. \*Thumboo J, Uramoto K, Shbeeb MI, O’Fallon WM, Crowson CS, Gibson LE, Michet CJ, **Gabriel SE**. Risk factors for the development of psoriatic arthritis: a population-based nested case-control study. *J Rheumatol* 2002;29(4):757-62.
12. Amadio PC, **Gabriel SE**, Yawn BP, Harmsen WS, Ilstrup DM, Hill J. Short-term outcomes of acute knee injuries: Does the provider make a difference? *Arthritis Care Res* 2002;47(4):361-5.
13. Leibson CL, Tosteson ANA, **Gabriel SE**, Ransom JE, Melton LJ III. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. *J Am Geriatrics Society* 2002;60(10):1644-50.
14. \*Bidaut-Russell M, **Gabriel SE**, Scott CG, Zinsmeister AR, Luthra HS, Yawn B. Determinants of patient satisfaction in chronic illness. *Arthritis Care Res* 2002;47(5):494-500.
15. **Gabriel SE**, Tugwell P, Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. *Ann Rheum Dis* 2002;61(4):370-3.
16. \*Doran MF, Crowson CS, O’Fallon WM, Hunder G, **Gabriel SE**. Trends in the incidence of polymyalgia rheumatica over a 30-year period in Olmsted County, Minnesota. *J Rheumatol* 2002;29:1694-7.
17. \*Cuddihy MT, **Gabriel SE**, Sloan JA, Crowson CS, Melton LJ III. Osteoporosis health beliefs among postmenopausal women with a history of distal forearm fracture. *Clin J Women’s Health* 2002;2(2):79-87.
18. \*Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, **Gabriel SE**. Epidemiology of gout: is the incidence rising?

*J Rheumatol* 2002;29:2403-6.

1. \*Doran MF, Crowson CS, Pond GR, O’Fallon WM, **Gabriel SE**. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. *Arthritis Rheum* 2002;46(9):2287-93.
2. \*Doran MF, Crowson CS, Pond GR, O’Fallon WM, **Gabriel SE**. Predictors of infections in rheumatoid arthritis.

*Arthritis Rheum* 2002;46(9):2294-300.

1. Bidaut-Russell M, **Gabriel SE,** Scott CG, Zinsmeister AR, Luthra HS, Yawn B. Determinants of patient satisfaction in chronic illness. Arthritis Rheum. 2002 Oct 15; 47(5):494-500. PMID: 12382297
2. **Gabriel SE**, Crowson, CS, Maradit Kremers H, Doran MF, Turesson C, O’Fallon WM, Matteson EL. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. *Arthritis Rheum* 2003;48(1):54-8.
3. \*Kamath CC, Maradit Kremers H, Vanness DJ, O’Fallon WM, Cabanela R, **Gabriel SE**. The cost effectiveness of acetaminophen, NSAIDs and selective Cox-2 inhibitors in the treatment of symptomatic knee osteoarthritis. *Value Health* 2003;6(2)144-57.
4. **Gabriel SE**, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P. OMERACT 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. *J Rheumatol* 2003;30(4):886-90.
5. Melton LJ III, **Gabriel SE**, Crowson CS, Tosteson ANA, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. *Osteoporos Int* 2003;14(5):383-8.
6. Turesson C, O’Fallon WM, Crowson CS, **Gabriel SE**, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis; incidence trends and risk factors over 46 years. *Ann Rheum Dis* 2003;62(8):722-7.
7. \*Maradit Kremers H, Bidaut-Russell M, Scott CG, Reinalda MS, Zinsmeister AR, **Gabriel SE**. Preventive medical services among patients with rheumatoid arthritis. *J Rheumatol* 2003;30(9):1940-7.
8. Proven A, **Gabriel SE**, Orces C, O’Fallon WM. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. *Arthritis Care Res* 2003;49(5):703-8.
9. Weisman M, Gano AD, **Gabriel SE**, Hochberg MC, Kavanaugh A, Liang MH, Ofman JJ, Prashker M, Suarez- Almazor ME, Yelin E, Nakelsky SD, Croft JD. Reading and interpreting economic evaluations in rheumatoid arthritis: An assessment of selected instruments for critical appraisal. *J Rheumatol* 2003;30:1739-47.
10. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, **Gabriel SE**, on behalf of the OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. *J Rheumaol* 2003;30(4):891-6.
11. Maradit Kremers H, Crowson CS, **Gabriel SE**. Rochester epidemiology project: a unique resource for research in the rheumatic diseases. *Rheum Dis Clin North Am* 2004;30(4):819-34.
12. **Gabriel SE**, Lymp JF, O’Fallon WM, Reinalda MS, Kamath CC, Nayar VR, Seltman KD. Why patients choose academic medical centers for their care: Findings and implications from Mayo Clinic. *Group Practice J* 2004;53(2):25-31.
13. \*Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, **Gabriel SE.** Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. *Arthritis Rheum* 2004;51(2):264-8.
14. \*Doran MF, Crowson CS, O’Fallon WM, **Gabriel SE**. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population-based study. *J Rheumatol* 2004;31(2):207-13.
15. Aubry MC, Riehle DL, Edwards WE, Maradit Kremers H, Roger VL, Sebo TJ, **Gabriel SE.** B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. *J Cardiovascular Pathol* 2004;13:233-6.
16. \*Cuddihy MT, Amadio PC, **Gabriel SE**, Pankratz VS, Kurland RL, Melton LJ III. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. *Osteoporos Int* 2004;15:695- 700.
17. \*Maradit Kremers H, Nicola P, Crowson CS, O’Fallon WM, **Gabriel SE**. Therapeutic strategies in rheumatoid arthritis over a 40-year period. *J Rheumatol* 2004;31(12):2366-73.
18. \*Maradit Kremers H, Nicola PJ, Crowson CS, Ballman KV, **Gabriel SE**. Prognostic importance of low body mass index on cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheum*. 2004;50(11):3450-7.
19. \*Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ**, Gabriel SE**. Increased unrecognized coronary heart disease in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005;52(2)402-11.
20. \*Nicola PJ, Maradit Kremers H, Roger VL, Jacobsen, SJJ, Crowson CS, Ballman KV, **Gabriel SE**. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. *Arthritis Rheum* 2005;52(2):412-20.
21. \*Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, **Gabriel SE.** Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005;52(3):722-32.
22. \*Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, **Gabriel SE**. Direct medical costs of polymyalgia rheumatica. *Arthritis Care Res* 2005;53(4):578-84.
23. \*Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, **Gabriel SE.** Relapse in a population-based cohort of patients with polymyalgia rheumatica. *J Rheumatol* 2005;32:65-73.
24. \*Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, **Gabriel SE**. Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. *Arthritis Care Res* 2005;53(3):395-403.
25. \*Crowson CS, Nicola PJ, Maradit Kremers H, O’Fallon WM, Therneau TM, Jacobsen, SJ, Roger VL, Ballman KV, **Gabriel SE**. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? *Arthritis Rheum* 2005;52(10):3039-44.
26. \*Gonzalez A, Maradit Kremers H, Crowson CS, **Gabriel SE**. Survival trends and risk factors for mortality in rheumatoid arthritis. *Int J Advances Rheum* 2005;3(2)38-43.
27. \*Nicola PJ, Crowson CS, Maradit Kremers H, Ballman KV, Roger VL, Jacobsen SJ, **Gabriel SE**. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. *Arthritis Rheum* 2006;54(1):60-7.
28. Vanness DJ, Tosteson ANA, **Gabriel SE,** Melton LJ. The need for microsimulation to evaluate osteoporosis interventions. Osteoporos Int. 2005 Apr; 16(4):353-8. PMID: 156453198
29. \*Maradit Kremers H, Nicola PJ, Crowson CS, O’Fallon WM, **Gabriel SE**. Patient, disease and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of rheumatoid arthritis patients. *J Rheumatol* 2006;33(2):248-55.
30. \*Maradit Kremers H, **Gabriel SE**. Rheumatoid arthritis and the heart. *Curr Heart Fail Rep* 2006;3:57-63.
31. \*Maradit Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacobsen SJJ, Roger VL, **Gabriel SE**. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. *Ann Rheum Dis* 2007;66:76-80.
32. \*Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM III, Hunder GG, **Gabriel SE**. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. *Arthritis Care Res* 2007;57(2):279-86.
33. Aubry C-M, Maradit Kremers H, Reinalda MS, Crowson CS, Edwards WD, **Gabriel SE**. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. *J Rheumatol* 2007;34(5):937-42.
34. \*Maradit Kremers H, McEvoy MT, Dann FJ, **Gabriel SE**. Heart disease in psoriasis. *J Am Acad Dermatol*

2007;57(2):347-54.

1. \*Davis JM III, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, **Gabriel SE**. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2007;56(3):820-30.
2. Bursi F, Weston SA, Killian JM, **Gabriel SE**, Jacobsen SJ, Roger VL. C-reactive protein and heart failure after myocardial infarction in the community. *Am J Med* 2007;120:616-22.
3. \*Crowson CS, Therneau TM, Matteson EL, **Gabriel SE**. Primer: demystifying risk – understanding and communicating medical risks. *Nat Clin Pract Rheum* 2007;3(3):181-7.
4. \*Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, Roger VL, **Gabriel SE**. The widening mortality gap between Rheumatoid Arthritis subjects and the general population. *Arthritis Rheum* 2007;56(11):3583-7.
5. Solomon DH, **Gabriel SE.** Quality Measures 101: what every rheumatologist should know. Clinical & Experimental Rheumatology. 2007 Nov-Dec; 25(6 Suppl 47): S18-S21.
6. \*Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, **Gabriel SE**. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-RA patients? *Ann Rheum Dis* 2008;67(1):64-9. PMID:17517756.
7. Helmick CG, Felson DT, Lawrence RC, **Gabriel SE**, Hirsch R, Maradit Kremers H, Kwoh CK, Liang MH, Mayes MD Merkel PA, Pillemer SR, Reveille JD. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. *Arthritis Rheum* 2008;58(1):15-25. PMID:18163481.
8. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, **Gabriel SE**, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Maradit Kremers H, Wolfe F. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. *Arthritis Rheum* 2008;58(1):26-35. PMCID: PMC3266664.
9. \*Maradit Kremers H, Crowson CS, **Gabriel SE**. Cardiovascular risk factors in rheumatoid arthritis. *Curr Med Literature-Rheumatol* 2008;27(1):1-12. [Review].
10. \*Gonzalez A, Icen M, Maradit Kremers H, Crowson CS, Davis JM, Therneau TM, Roger VL, **Gabriel SE**. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. *J Rheumatol* 2008;35(6):1009-14. PMCID: PMC2834198.
11. \*Maradit Kremers H, Crowson CS, Therneau TM, Roger VL, **Gabriel SE**. High 10-year risk of cardiovascular disease in newly diagnosed Rheumatoid Arthritis (RA) patients. *Arthritis Rheum* 2008;58(8):2268-74. PMCID: PMC2929699.
12. Huskins WC, Weavers K, Gorden J, **Gabriel SE.** Creating the future: training the next generation of translational science teams. *Clin Transl Sci* 2008;1(2):94-5. PMCID: PMC2990195.
13. **Gabriel SE**. Cardiovascular morbidity and mortality in rheumatoid arthritis. *Am J Med (RA Supplement)*

2008;121(10A):S9-S14. [Review] PMCID: PMC2858687.

1. \*Davis JM, 3rd, Roger VL, Crowson CS, Maradit Kremers H, Therneau TM, **Gabriel SE**. The presentation and outcome of heart failure in subjects with rheumatoid arthritis differs from that of the general population. *Arthritis Rheum* 2008;58(9):2603-11. PMCID: PMC2631416.
2. **Gabriel SE**. Why do persons with rheumatoid arthritis still die prematurely? *Ann Rheum Dis* 2008;67(Suppl 3):iii 30-4. [Review] PMCID: PMC2830861.
3. \*Icen M, Crowson CS, McEvoy MT, **Gabriel SE**, Maradit Kremers H. Potential misclassification of psoriasis patients in electronic databases. *J Am Acad Dermatol* 2008;59:981-5. PMCID: PMC2840380.
4. \*Singh JA, **Gabriel SE**, Lewallen D. The impact of gender, age and pre-operative pain severity on pain following total knee arthroplasty. *Clin Orthop Relat Res* 2008;466:2717-23. PMCID: PMC256503.
5. \*Icen M, Nicola PJ, Maradit-Kremers H, Crowson CS, Therneau TM, Matteson EL, **Gabriel SE**. Systemic lupus erythematosus features in rheumatoid arthritis and their effect on overall mortality. *J Rheumatol* 2009;36:50-7. PMCID: PMC2836232.
6. Wilson FC, Icen M, Crowson CS, McEvoy MT, **Gabriel SE**, Maradit Kremers H. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. *Arthritis Rheum* 2009;61(2):233-9. PMCID: PMC3061343.
7. Wilson FC, Icen M, Crowson CS, McEvoy MT, **Gabriel SE**, Maradit Kremers H. Time trends in epidemiology and characteristics of psoriatic arthritis over three decades: a population-based study. *J Rheumatol* 2009;36:361-7. PMCID: PMC2717703.
8. \*Icen M, Crowson CS, McEvoy MT, Dann FJ, **Gabriel SE**, Maradit Kremers H. Trends in the incidence of adult- onset psoriasis over three decades: a population-based study. *J Am Acad Dermatol* 2009; 60(3):394-401. PMCID: PMC3028518.
9. Calamia K, Wilson F, Icen M, Crowson CS, **Gabriel SE**, Maradit Kremers H. Epidemiology and clinical characteristics of Behcet’s disease in the United States: a population-based study. *Arthritis Rheum* 2009;61(5):600- 4. PMCID: PMC3024036.
10. Warrington KJ, Jarpa E, Crowson CS, Cooper LT, Hunder GG, Matteson EL, **Gabriel SE**. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. *Arthritis Res Ther* 2009;11(2):R50. PMCID: PMC2688201.
11. **Gabriel SE**, Michaud K. Epidemiological studies in incidence, prevalence, mortality and comorbidity of the rheumatic diseases. *Arthritis Res Ther* 2009;11:229 [Review] PMCID: PMC2714099.
12. \*Reading S, Crowson CS, Rodeheffer R, Fitz-Gibbon P, Maradit Kremers H, **Gabriel SE**. Do rheumatoid arthritis patients have a higher risk for sleep apnea? *J Rheumatol* 2009;36(9):1869-72. PMCID: PMC2834190.
13. \*Liang KP, Maradit Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, **Gabriel SE**. Autoantibodies and the risk of cardiovascular events. *J Rheumatol* 2009;36(11):2462-9. PMCID: PMC2837072.
14. Singh JA, **Gabriel SE**, Lewallen D. Gender and arthroplasty type affect prevalence of moderate-severe pain post total hip arthroplasty. *Ann Rheum Di*s. 2011 Dec;70(12):2082-8. PMCID: PMC3315837.
15. Icen M, Crowson CS, McEvoy MT, Dann FJ, **Gabriel SE**, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009 Mar; 60(3):394-401. PMCID: PMC3028518.
16. Davis JM 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, **Gabriel SE.** Reply. Arthritis Rheum. 2009 Jul;

6097): 2206-7. PMID 19565511

1. **Gabriel SE**. Heart Disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis. 2010 Jan; 69 Suppl 1:i61-64. PMCID:PMC4308040.
2. **Gabriel SE**. Shaping our own future. Arthritis Rheum. 2010 Feb; 62(2):307-10. PMCID – NA
3. Ade A, **Gabriel SE**,. Addressing musculoskeletal health inequity in Africa. Arthritis Care Res. 2010; 62(4): 439-41.
4. \*Myasoedova E, Crowson CS, Maradit Kremers H, Fitz-Gibbon P, Therneau TM, **Gabriel SE**. Total cholesterol and LDL levels decrease before the onset of rheumatoid arthritis. *Ann Rheum Dis* 2010;69;1310-4. PMCID: PMC2890039.
5. \*Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Ytterberg SR, Matteson EL, Warrington KJ. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. *Arthritis Care Res* 2010;62(2)149-54. PMCID: PMC2874240.
6. \*Crowson CS, Liang KP, Therneau TM, Maradit Kremers H, **Gabriel SE**. Could accelerated aging explain the excess mortality in seropositive rheumatoid arthritis patients? *Arthritis Rheum* 2010;62(2)378-82. PMCID: PMC2929694.
7. \*Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Ytterberg SR, Matteson EL, **Gabriel SE**, Warrington KJ. Cancer preceding giant cell arteritis: a case-control study. *Arthritis Rheum* 2010;62(6)1763-9. PMCID: PMC2908278.
8. \*Myasoedova E, **Gabriel SE**. Cardiovascular disease in rheumatoid arthritis: a step forward. *Curr Opin Rheumatol* 2010;22:342-7. [Review]. PMCID –NA.
9. \*Myasoedova E, Crowson CS, Maradit Kremers H, Therneau TM, **Gabriel SE**. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. *Arthritis Rheum* 2010;62(6):1576-82. PMCID: PMC2929692.
10. Nannini C1, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL, Bongartz T.. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. *Art Arthritis Care Res (Hoboken).* 2013 Aug;65(8):1243-50. PMCID: PMC4017238.
11. \*Singh JA, **Gabriel S**, Lewallen D. Higher body mass index is not associated with worse pain outcomes after primary or revision total knee arthroplasty (TKA). *J Arthroplasty* 2011;26(3):366-74. PMCID: PMC2930933.
12. \*Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, Borgeson DD, Therneau TM, Rodeheffer RJ, **Gabriel SE**. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. *Ann Rheum Dis* 2010;69:1665-70. PMCID: PMC2920362.
13. \*Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, **Gabriel SE**. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. *J Immunol* 2010;184:7297-304. PMCID: PMC2882518.
14. Schäfer VS, Kermani TA, Crowson CS, Hunder GG, **Gabriel SE**, Ytterberg SR, Matteson EL, Warrington KJ. Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. *Rheumatol (Oxford);* 2010;49:2104-8. PMCID: PMC2981027.
15. \*Myasoedova E, Davis JM III, Crowson CS, **Gabriel SE**. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. *Curr Rheumatol Rep* 2010;12:379-85. [Review]. PMCID – NA.
16. Hoganson DD, Crowson CS, Warrington KJ, **Gabriel SE**, Matteson EL. Lack of association of high body mass index with risk for developing polymyalgia rheumatica. *Int J Rheum Dis* 2010;13(3):e1-5. PMCID: PMC4012353.
17. Borkhoff CM, Wieland M, Myasoedova E, Ahmad Z, Welch V, Hawker GA, Li LC, Buchbinder R, Ueffing E, Beaton D, Cardiel MH, **Gabriel SE**, Guillemin F, Adebajo AO, Bombardier C, Chahlia N, Hajjaj-Hassouni N, Tugwell P. Reaching those most in need: a scoping review of interventions to improve health care quality for disadvantaged populations with osteoarthritis. *Arthritis Care Res* 2010;63(1):39-52. PMCID – NA.
18. Jackson R, **Gabriel SE**, Pariser A, Feig P. Training the translational scientist. *Sci Transl Med* 2010;22;2(63):mr2. PMCID – NA.
19. Richards BL, March L, **Gabriel SE**. Epidemiology of large-vessel vasculidities. *Best Pract Res Clin Rheumatol*

2010;24(6):871-83. PMCID – NA.

1. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, **Gabriel SE.** The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 Mar; 63(3):633-9. PMCID: PMC3078757.
2. Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM, Fitz-Gibbon PD, Rodeheffer RJ, **Gabriel SE**. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. *J Rheumatol* 2011;38(1):29-35. PMCID: PMC3014403.
3. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM III, Hunder GG, Therneau TM, **Gabriel SE**. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. *Arthritis Rheum* 2011;63(3):633-9. PMCID: PMC3078757.
4. \*Myasoedova E, Crowson CS, Maradit Kremers H, Roger VL, Fitz-Gibbon PD, Therneau TM, **Gabriel SE**. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. *Ann Rheum Dis* 2011;70(3):482-7. PMCID: PMC3058921.
5. Kitas GD, **Gabriel SE**. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. *Ann Rheum Dis* 2011;70:8-14. [Review]. PMCID – NA.
6. Crowson CS, Myasoedova E, Davis JM III, Roger VL, Karon BL, Borgeson D, Rodeheffer RJ, Therneau TM, **Gabriel SE**. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. *Arthritis Care Res* 2011;63(5):729-34. PMCID: PMC3091972.
7. \*Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, **Gabriel SE**. A signature of aberrant responsiveness of the peripheral immune system predicts the 6-month risk of infections in rheumatoid arthritis. *Arthritis Rheum.* 2011;63(6):1497-506. PMCID: PMC3106129.
8. \*Myasoedova E, Crowson CS, Turesson C, **Gabriel SE**, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. *J Rheumatol* 2011:38(6):983-9. PMCID: PMC3193155.
9. Arruda-Olson AM, Roger VL, Chai HS, de Andrade M, Fridley BL, Cunningham JM, **Gabriel SE,** Bielinski SJ. Association of TNFSF8 polymorphisms with peripheral neutrophil count. *Mayo Clin Proc* 2011;86(11):1075-81. PMCID: PMC3202998.
10. Singh JA, Jensen MR, Harmsen WS, **Gabriel SE,** Lewallen DG. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. *Ann Rheum Dis.* 2011;70(12):2082-8. PMCID: PMC3315837.
11. \*Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL, Therneau TM, **Gabriel SE.** The influence of rheumatoid arthritis disease characteristics on heart failure. *J Rheumatol* 2011;38(8):1601-6. PMCID: PMC3337549.
12. Kremers HM, Myasoedova E, Crowson CS, Savova G, **Gabriel SE,** Matteson EL. The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. *Rheumatology (Oxford).* 2011;50(1):6-15. PMCID: PMC3716332.
13. Krause ML, Davis JM 3rd, Knutson KL, Strausbach MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL,

**Gabriel SE**. Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. *Clin Immunol* 2011;141(1):67-72. PMCID: PMC3183136.

1. **Cancer Genome Atlas Research Network.** Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417: 519-25. Sep 09. PMCID: PMC: 3466113.
2. **Gabriel SE,** Normand SL. Getting the methods right—the foundation of patient-centered outcomes research. N Engl J Med. 2012 Aug 30; 367(9): 787-90. 2012 July 25. PMCID-NA.
3. Bacani AK, **Gabriel SE,** Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? *Arthritis Rheum* 2012;64(1):53-61. PMCID: PMC3474372.
4. Shourt CA, Crowson CS, **Gabriel SE**, Matteson EL. Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality. *J Rheumatol.* 2012;39(3):481-5. PMCID: PMC3634337.
5. Davis JM III, Knutson KL, Skinner JA, Strausbuach MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, **Gabriel SE.** A profile of immune response to herpesvirus is associated with radiographic damage in rheumatoid arthritis. *Arthritis Res* 2012;14(1):R24. PMCID: PMC3392817.
6. McCoy SS, Crowson CS, **Gabriel SE**, Matteson EL. Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. *J Rheumatol* 2012;39(5):954-8. PMCID: PMC3518421.
7. **Gabriel SE**, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. *Curr Opin Rheumatol.*

2012;24(2):171-6. PMCID – NA.

1. Crowson CS, Matteson EL, Roger VL, Therneau TM, **Gabriel SE**. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. *Am J Cardiol* 2012;110(3):420-4. PMCID: PMC3398213.
2. Basch E, Aronson N, Berg A, Flum D, **Gabriel SE**, Goodman SN, Helfand M, Ioannidis JP, Lauer M, Meltzer D, Mittman B, Newhouse R, Normand SL, Schneeweiss S, Slutsky J, Tinetti M, Yancy C. Methodological standards and patient-centeredness in comparative effectiveness research: PCORI perspective. *JAMA* 2012;307(15):1636-40. PMCID – NA.
3. Veetil BM, Myasoeodova E, Matteson EL, **Gabriel SE**, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based study. *Arthritis Care Res* 2013;65(6):854-61. PMCID: PMC3674119.
4. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, **Gabriel SE**, Matteson EL. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. *Ann Rheum Dis* 2013;72(12):1989-94. PMCID: PMC4112513.
5. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG,

Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, **Gabriel SE**, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina- Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi- Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2197-223. PMID: PMC23245608.

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, **Gabriel SE**, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R,

Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012 Dec 15;380(9859):2163-96. PMID: PMC23245607.

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, **Gabriel SE**, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2095-128. PMID: PMC23245604.
2. Yun HD, Knoebel E, Fenta Y, **Gabriel SE**, Leibson CL, Loftus EV Jr, Roger V, Yawn BP, Li B, Juhn YJ. Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. *Mayo Clin Proc* 2012(10):953-60. PMCID: PMC353839.
3. Crowson CS, Matteson EL, Davis JM, **Gabriel SE**. Contribution of obesity to the rise in incidence of rheumatoid arthritis. *Arthritis Care Res* 2013;65(1):71-7. PMICD: PMC3707391.
4. Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, **Gabriel SE**, Matteson EL, Bongartz T. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. *Arthritis Care Res* 2013;65(8):1243-50. PMCID: PMC4017238.
5. Myasoedova E, David JM, Crowson CS, Roger V, Karon BL, Borgeson DD, Therneau TM, Matteson EL, Rodeheffer RJ, **Gabriel SE**. Brief Report: Rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. *Arthritis Rheum* 2013;65(7):1713-8. PMCID: PMC3914147.
6. McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, **Gabriel SE**. Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. *J Rheumatol* 2013;40(5):605-10. PMCID: PMC3895921.
7. Akkara Veetil BM, Myasoedova E, Matteson EL, **Gabriel SE**, Crowson CS. Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. *J Rheumatol* 2013;40(7):1082-8. PMCID: PMC3891914.
8. Murray CJ, Abraham J, Ali MK, Alvarado M, Atkinson C, Baddour LM, Bartels DH, Benjamin EJ, Bhalla K, Birbeck G, Bolliger I, Burstein R, Carnahan E, Chen H, Chou D, Chugh SS, Cohen A, Colson KE, Cooper LT, Couser W, Criqui MH, Dabhadkar KC, Dahodwala N, Danaei G, Dellavalle RP, Des Jarlais DC, Dicker D, Ding EL, Dorsey ER, Duber H, Ebel BE, Engell RE, Ezzati M, Felson DT, Finucane MM, Flaxman S, Flaxman AD, Fleming T, Forouzanfar MH, Freedman G, Freeman MK, **Gabriel SE**, Gakidou E, Gillum RF, Gonzalez-Medina D, Gosselin R, Grant B, Gutierrez HR, Hagan H, Havmoeller R, Hoffman H, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Kassebaum N, Khatibzadeh S, Knowlton LM, Lan Q, Leasher JL, Lim S, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Macintyre MF, Mallinger L, McDermott MM, Meltzer M, Mensah GA, Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad AH, Moran AE, Mozaffarian D, Murphy T, Naghavi M, Narayan KM, Nelson RG, Olives C, Omer SB, Ortblad K, Ostro B, Pelizzari PM, Phillips D, Pope CA, Raju M, Ranganathan D, Razavi H, Ritz B, Rivara FP, Roberts T, Sacco RL, Salomon JA, Sampson U, Sanman E, Sapkota A, Schwebel DC, Shahraz S, Shibuya K, Shivakoti R, Silberberg D, Singh GM, Singh D, Singh JA, Sleet DA, Steenland K, Tavakkoli M, Taylor JA, Thurston GD, Towbin JA, Vavilala MS, Vos T, Wagner GR, Weinstock MA, Weisskopf MG, Wilkinson JD, Wulf S, Zabetian A, Lopez AD. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. *JAMA* 2013;310:591-608. PMCID – NA.
9. Myasoedova E, **Gabriel SE**, Green AB, Matteson EL, Crowson CS. Impact of statin use on lipid levels in statin- naïve patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study. *Arthritis Care Res* 2013;65(10):1592-9. PMCID: PMC3788038.
10. Crowson CS, Therneau TM, Davis JM, Roger VL, Matteson EL, **Gabriel SE**. Brief Report: Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis. *Arthritis Rheum* 2013;65(10):2562-6. PMCID: PMC3966134.
11. Amin S, **Gabriel SE**, Achenbach SJ, Atkinson EJ, Melton LJ. Are young women and men with rheumatoid arthritis at risk for fragility fracture: a population-based study. *J Rheumatol* 2013;40(10):1669-76. PMCID: PMC3910326.
12. Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, **Gabriel SE**. Rheumatoid arthritis and cardiovascular disease. *Am Heart J* 2013;166(4):622-8. PMCID: PMC3890244.
13. Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson CS, Therneau TM, Matteson EL, **Gabriel SE**. Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. *Arthritis Res Ther* 2013;15(6):R199. PMCID: PMC3978471.
14. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, **Gabriel SE**, Lassere M, Johns N, Buchbinder R, Woolf A, March L. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014 Feb 18. PMID – 24550173.
15. Jebakumar AJ, Udayakumar PD, Crowson CS, **Gabriel SE**, Matteson EL. Occurrence and effect of lower extremity ulcer in rheumatoid arthritis -- a population-based study. *J Rheumatol* 2014;41(3):437-43. PMCID: PMC4251738.
16. Hickson LJ, Crowson CS, **Gabriel SE**, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. *Am J Kidney Dis* 2014;63(2):206-13. PMCID: PMC3944015.
17. Wright K, Crowson CS, **Gabriel SE**. Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

*Heart Fail Clin* 2014;10(2):339-52. PMCID: PMC3964373.

1. Pfeifer EC, Crowson CS, Amin S, **Gabriel SE,** Matteson EL. The influence of Early Menopause on Cardiovascular Risk in Women with Rheumatoid Arthritis. J Rheumatol. 2014 Jul;41(7):1270-5. PMCID: PMC24882842.
2. Semb AG, Rollefstad S, van Riel P, Kitas GD, Matteson EL, **Gabriel SE**. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. *Ann Rheum Dis*. 2014 Jul;73(7):1284-8. PMCID: PMC24608403.
3. Myasoedova E, Crowson, CS, Green AB, Matteson EL, **Gabriel SE**. Long-term blood pressure variability in patients with rheumatoid arthritis (RA) and its impact on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study. J Rheumatol. 2014 Aug;41(8):1638-44. PMCID: PMC4159667.
4. Mankad R, **Gabriel SE.** Rheumatoid arthritis: Treating Cardiovascular risk in RA requires multidisciplinary care. Nat Rev Rheumatol. 2014 Apr; 10(4):202-4. PMCID: PMC24637364.
5. Makol A, Davis JM 3rd, Crowson CS, Therneau TM, **Gabriel SE**, Matteson EL. Time trends in glucocorticoid use

in rheumatoid arthritis: Results from a population based inception cohort 1980-1994 vs. 1995-2007. *Arthritis Care Res (Hoboken).* 2014 Oct;66(10):1482-8. PMCID: PMC4177279

1. Kuo D, Crowson CS, **Gabriel SE**, Matteson EL. Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis. *International Journal of Rheumatology.* Int J Rheumatol. 2014;2014:523897. PMCID: PMC4150464.
2. Fine NM, Crowson CS, Lin G, Oh JK, Villarraga HR, **Gabriel SE**. Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography. Ann Rheum Dis. 2014 Oct;73(10):1833-9. *Ann Rheum Dis* 2014 Sept. 7. PMCID: PMC3895498
3. Prasad M, Herrmann J, **Gabriel SE**, Weyand CM, Mulvagh S, Makad R, Oh J, Matteson E, Lerman A. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015 Mar;12(3):168-176 *Nat Rev Cardiol.* 2014 Dec 23. PMID: 25533796.
4. Chauha K, Ackerman M, Crowson CS, Matteson EL, **Gabriel SE**. Population-based study of QT Interval Prolongation in Patients with Rheumatoid Arthritis. Clin Exp Rheumatol. 2015 Jan-Feb;33(1):84-9 *Clinical and Experimental Rheumatology On Line. Clin Exp Rheumatol.* 2015 Jan 8. PMID: 25572282.
5. Chu LH, Kawatkar AA, **Gabriel SE.** Medication Adherence and Attrition to Biologic Treatment in Rheumatoid Arthritis Patients. Clin Ther. 2015 Mar 1;37(3):660-666. PMID: 25618317.
6. Deng X, Crowson CS, Rajkumar SV, Dizpenzieri A, Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann, **Gabriel SE**, Davis JM III. Elevation of Serum immunoglobulin free light chains during the pre-clinical period of rheumatoid arthritis: impact on mortality. J Rheumatol. 2015 Feb;42(2):181-7 *The Journal of Rheumatology.* PMCID: PMC4371213
7. Bacani K, Crowson CS, Roger VL, **Gabriel SE**, Matteson EL. Increased Incidence of Atrial Fibrillation in Patients with Rheumatoid Arthritis. *BioMed Research International.* 2015. PMCID: PMC 4359868
8. Woolf AD, **Gabriel SE.** Overcoming challenges in order to improve the management of rheumatic and musculoskeletal diseases across the globe. *Clin Rheumatol.* 2015 May;34(5):815-*7.* PMID: 25700667
9. Wing S, Rider LG, Johnson JR, Miller FW, Matteson EL, Crowson CS, **Gabriel SE**. Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence? *BMJ Open.* 2015 May 15;5(5). PMID: 25979866
10. Krause ML, Crowson CS, Bongartz T, Matteson EL, Michet CJ, Mason TG, Persellin ST, **Gabriel SE,** Davis JM 3rd. Determinants of Disability in Rheumatoid Arthritis. Open Rheumatol J. 2015 Nov 20;9:88-93. PMID: 26862353.
11. Kermani TA, Warrington KJ, Crowson CS, Hunder GG, Ytterberg SR, **Gabriel SE,** Matteson EL. Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis. J Clin Rheumatol. 2016 Jun;22(4):184-7. PMID 27219304.
12. Wang R, **Gabriel SE,** Ward MM. Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study. Arthritis Rheumatol. 2016 Jun;68(6):1415-21. PMID: 26663907
13. Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, **Gabriel SE**, Patel AR, Gargani L, Bombardieri S, Matucci-Cerinic M, Lombardi M, Pepe A, Aletras AH, Kolovou G, Miszalski T, van Riel P, Semb A, Gonzalez- Gay MA, Dessein P, Karpouzas G, Puntmann V, Nagel E, Bratis K, Karabela G, Stavropoulos E, Katsifis G, Koutsogeorgopoulou L, van Rossum A, Rademakers F, Pohost G, Lima JA. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. Int J Cardiol. 2016 Aug 15;217:135-48 PMID: 27179903.
14. Starr S, Reed D, Essary A, Hueston W, Johnson CD, Landman N, Meurer J, Miller B, Ogrinc G, Petty E, Raymond J, Riley W, **Gabriel SE**, Maurana C. Science of Health Care Delivery as a First Step to Advance Undergraduate Medical Education: A Multi-Institutional Collaboration. Healthcare: The Journal of Delivery Science and Innovation*.* Healthcare (2017), <http://dx.doi.org/10.1016/j.hjdsi.2017.01.003>.
15. Crowson CS, **Gabriel SE,** Semb AG, van Riel PLCM, Karpouzas G, Dessein PH, Hitchon C, Ramos VP, Kitas GD, on behalf of A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis. Rheumatoid arthritis- specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. *Rheumatology,* Volume 56, Issue 7, 1 July 2017, Pages 1102-1110. https://doi.org/10.1093/rheumatology/kex038.
16. Davis JM, Lin G, Oh J, Crowson CS, Achenbach SJ, Therneau TM, Matteson EL, Rodeheffer RJ, **Gabriel SE.** Five-Year Changes in Cardiac Structure and Function in Patients With Rheumatoid Arthritis Compared With the General Population. Int J Cardiol Mar 2017 Mar 31. pii: S0167-5273(16)34189-4. doi: 10.1016/j.ijcard.2017.03.108.
17. Crowson CS, Rollefstad S, Kitas GD, van Riel PLCM, **Gabriel SE**, Semb AG, on behalf of A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA). (2017). Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. *PLoS One.* 2017 Apr 7; 12(4), e0175605. doi: 10.1371/journal.pone.0175605.
18. Myasoedova E, **Gabriel SE**, Matteson EL, Davis JM, Therneau TM & Crowson CS. (2017) Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? The Journal of Rheumatology, 44 (6) 732-739
19. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, **Gabriel SE**, Matteson EL, Kvien TK, Douglas K, Sandoo A, Arts E, Wållberg-Jonsson S, Innala L, Karpouzas G, Dessein PH, Tsang L, EL-Gabalawy H, HItchon C, Ramos VP, Yáñez IC, Sfikakis PP, Zampeli E, Gonzalez-Gay MA, Corrales A, van de laar M, Vonkeman HE, Meek I, & Semb AG, on behalf of A Trans-Atlantic Cardivascular Consortium for Rheumatoid Arthritis (ATACC-RA) Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, Ann Rheum Dis.2017 Sep 6, pii: annrheumdis-2017- 211735. doi:1136/annrheumdis-2017-211735.

# Book Chapters and Theses (\*primary mentor for first author)

1. **Gabriel SE**. M.Sc. Thesis: A utility measurement instrument for NSAID induced adverse gastrointestinal events. Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada. Copyright 1990.
2. **Gabriel SE**. Soft tissue response to silicones (Chapter 7). *Handbook of biomaterial properties*, Edited by Black J, Hastings G. Chapman & Hall, London. Copyright 1998.
3. **Gabriel SE**. Classification of Rheumatic Diseases. *Rheumatology Second Edition*, Volume 1:3.1-4 Edited by Klippel JH, Dieppe PA. Mosby, London, England. Copyright 1998.
4. **Gabriel SE**. [Reviewer and editorial contributor] *Mayo Clinic Guide to Self-Care* (2nd Edition) Edited by Hagen

PT. Mayo Foundation for Medical Education and Research. Copyright 1999.

1. **Gabriel SE**. Epidemiology of the rheumatic diseases (Chapter 23). *Kelley’s Textbook of Rheumatology 6th Edition*, Volume 1 of 2. Edited by Ruddy S, et al. WB Saunders Company, Philadelphia. Copyright 2000.
2. **Gabriel SE**. The epidemiology of rheumatoid arthritis (Chapter 2) in ReMEDICA State of the Art Series: Rheumatoid Arthritis -- Epidemiology, Pathogenesis, and Treatment. ReMEDICA Publishing Limited, London. Copyright 2001.
3. **Gabriel SE**. Classification of the rheumatic diseases (Chapter 2) in *Rheumatology, 3rd Edition*. Edited by Hochberg

MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Mosby, London. Copyright 2003.

1. \*Maradit Kremers H, **Gabriel SE**, Drummond MF. Principles of health economics and application to rheumatic disorders (Chapter 7) in *Rheumatology, 3rd Edition*. Edited by Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Mosby, London. Copyright 2003.
2. \*Maradit Kremers H, **Gabriel SE**. Economics (Chapter 3) in *Evidence Based Rheumatology*. Edited by Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells GA. BMJ Publishing Group. London. Copyright 2004.
3. \* Maradit Kremers H, **Gabriel SE**. Epidemiology. In: St, Clair EW, Pisetsky DS, Haynes BF, editors. Rheumatoid arthritis. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1-10.
4. \* Maradit Kremers H, **Gabriel SE**. Epidemiology of the rheumatic diseases. In: Harris ED Jr. et al, editor.

*Kelley's Textbook of Rheumatology. 7th Edition. Volume 1*. Philadelphia: Saunders; 2005. p. 407-25.

1. \*Maradit Kremers H, Roger VL, **Gabriel SE**: Heart disease associated with rheumatoid arthritis. Zipes DP, Libby P, Bonow RO, Braunwald E (eds): *Braunwald's Heart Disease, 7th ed.* Philadelphia: Elsevier, [www.braunwalds.com,](http://www.braunwalds.com/) 2006.
2. \*Maradit Kremers H, **Gabriel SE**, Drummond D. Principles of health economic and application to rheumatic disorders and pharmaconomics. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. *Rheumatology.* Vol 1. 4th edition: Elsevier Limited; 2007.
3. \*Maradit Kremers H, **Gabriel SE**, Drummond D. Principles of health economic and application to rheumatic disorders. In:, Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. *Rheumatology.* Vol 1. 5th edition: Elsevier Limited; 2010.
4. **Gabriel SE**. The ACR: A Worldwide Organization. In: *American College of Rheumatology 75th Anniversary*

*Reader. Arthritis Rheum* 2010.

1. **Gabriel SE**. News in the Epidemiology of Rheumatic Diseases. In: *Rheumatology for the Patient*. Oslo, Norway: Diakonhjemmet Hospital, Publisher; 2009.
2. Noseworthy J, **Gabriel SE.** Health Systems as a research platforms: enhancing science, value, and innovation. In: Institute of Medicine: Patients Charting The Course: Citizen Engagement and the Learning Health System: Workshop Summary: National Academies Press; 2011. 2, Clinical Research, Patient Care, and Learning That is Real-Time and Continuous.
3. Kitas GD, **Gabriel SE**. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8-14.
4. **Gabriel SE**, Symmons D. Cardiovascular Risk in Rheumatic Disease. In: Firestein G, editor. Kelley's Textbook of Rheumatology 9e: Elsevier, Inc.; 2012.
5. Myasoedova E., **Gabriel S.E.** Chapter 1. Overview of rheumatoid arthritis and mortality in relation to cardiovascular disease. Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis/ Edited by A.G.Semb. Springer International Publishing. Switzerland 2016. Pages 1-17. Total pages: 128.

# Books

* 1. Firestein GS, O’Dell JR, Budd RC, McInnes IB, **Gabriel SE** (Eds). *Kelley’s Textbook of Rheumatology, 9th Edition*. Elsevier Publications, 2011.
  2. Firestein GS, O’Dell JR, Budd RC, McInnes IB, **Gabriel SE** (Eds). *Kelley’s Textbook of Rheumatology, 10th*

*Edition*. Elsevier Publications, 2016

# Editorials/Commentaries/Perspectives/Reviews

1. **Gabriel SE**, Bombardier C. NSAID induced ulcers. An emerging epidemic? [editorial] *J Rheumatol*

1990;17(1):1-4.

1. **Gabriel SE**. Is misoprostol prophylaxis indicated for NSAID induced adverse gastrointestinal events? An epidemiologic opinion. [editorial] *J Rheumatol* 1991;18(7):958-61.
2. **Gabriel SE**, Jaakkimainen L, Bombardier C. Nonaspirin NSAIDs and adverse gastrointestinal events: A meta- analysis [editorial]. *ACP Journal Club* 1992;116(Suppl 2):60.
3. **Gabriel SE**. Commentary on international opinion poll on drug-related gastroduodenal lesions. *Gastroenterol Int*

1994;7(1):41-2.

1. **Gabriel SE**. Dear Colleague…Gastroenterology, *Care Cure Communications* 1995; No. 2.
2. Katz JN**,** Liang MH, **Gabriel SE**, Cleary PD. Features of male versus female patients undergoing surgery for osteoarthritis. *Arthritis Rheum* 1995;38:448.
3. Talley NJ, **Gabriel SE**, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. *Gastroenterol* 1995;109(6):1736-41.
4. **Gabriel SE**. Insufficient information exists about the overall health risk associated with silicone gel breast implants. [Commentary] *ACP Journal Club* 1996;125(1):21.
5. **Gabriel SE**. The threat to population-based research [editorial review]. *Curr Opin Rheumatol* 1997;9:87-9.
6. **Gabriel SE**. Adverse effects of therapy for polymyalgia rheumatica [commentary by Brett AS]. *J Watch*

1997;17(22):178.

1. **Gabriel SE**. Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use? [Editorial] *Italian J Gastroenterol Hepatol* 1998;30(2):139-42.
2. **Gabriel SE**. Epidemiology and health services research [Editorial Overview]. *Curr Opin Rheumatol* 1998;10: 121-2.
3. **Gabriel SE**. Controversies in economic evaluation in the rheumatic diseases. [Editorial comment] *J Rheumatol*

1999;26(9):1859-60.

1. **Gabriel SE**. Epidemiology and health services research. [Editorial Overview]. *Curr Opin Rheumatol*

1999;11(2):89-90.

1. **Gabriel SE**. The epidemiology of rheumatoid arthritis. *Rheum Dis Clin North Am* 2001;27(2):269-81.
2. \*Doran MF, **Gabriel SE**. Infections in rheumatoid arthritis: A new phenomenon? [Editorial] *J Rheumatol*

2001:28(9):1942-3.

1. \*Montori VM, Basu A, Erwin PJ, Velosa JA, **Gabriel SE**, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care* 2002;25(3):583-92. [Review]
2. Boers M, Dijkmans BAC, **Gabriel SE**, Maradit Kremers H, O’Dell JR, Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. *Arthritis Rheum* 2004; 50(6):1734-9.
3. Vanness DJ, Tosteson AN, **Gabriel SE**, Melton LJ III. The need for microsimulation to evaluate osteoporosis interventions. *Osteoporosis Int* 2005;16:353-8.
4. **Gabriel SE**. Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use? [Editorial] *Italian J Gastroenterol Hepatol* 1998;30(2):139-42.
5. **Gabriel SE**. Epidemiology and health services research [Editorial Overview]. *Curr Opin Rheumatol* 1998;10:121- 2.
6. **Gabriel SE**. Controversies in economic evaluation in the rheumatic diseases. [Editorial comment] *J Rheumatol*

1999;26(9):1859-60.

1. **Gabriel SE**. Epidemiology and health services research. [Editorial Overview]. *Curr Opin Rheumatol*

1999;11(2):89-90.

1. **Gabriel SE**. The epidemiology of rheumatoid arthritis. *Rheum Dis Clin North Am* 2001;27(2):269-81.
2. \*Doran MF, **Gabriel SE**. Infections in rheumatoid arthritis: A new phenomenon? [Editorial] *J Rheumatol*

2001:28(9):1942-3.

1. \*Montori VM, Basu A, Erwin PJ, Velosa JA, **Gabriel SE**, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care* 2002;25(3):583-92. [Review]
2. Boers M, Dijkmans BAC, **Gabriel SE**, Maradit Kremers H, O’Dell JR, Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. *Arthritis Rheum* 2004; 50(6):1734-9.
3. **Gabriel SE**. Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use? [Editorial] *Italian J Gastroenterol Hepatol* 1998;30(2):139-42.
4. **Gabriel SE**. Epidemiology and health services research [Editorial Overview]. *Curr Opin Rheumatol* 1998;10:121- 2.
5. **Gabriel SE**. Controversies in economic evaluation in the rheumatic diseases. [Editorial comment] *J Rheumatol*

1999;26(9):1859-60.

1. **Gabriel SE**. Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use? [Editorial] *Italian J Gastroenterol Hepatol* 1998;30(2):139-42.
2. **Gabriel SE**. Epidemiology and health services research [Editorial Overview]. *Curr Opin Rheumatol* 1998;10:121- 2.
3. **Gabriel SE**. Controversies in economic evaluation in the rheumatic diseases. [Editorial comment] *J Rheumatol*

1999;26(9):1859-60.

1. **Gabriel SE**. Epidemiology and health services research. [Editorial Overview]. *Curr Opin Rheumatol*

1999;11(2):89-90.

1. **Gabriel SE**. The epidemiology of rheumatoid arthritis. *Rheum Dis Clin North Am* 2001;27(2):269-81.
2. \*Doran MF, **Gabriel SE**. Infections in rheumatoid arthritis: A new phenomenon? [Editorial] *J Rheumatol*

2001:28(9):1942-3.

1. \*Montori VM, Basu A, Erwin PJ, Velosa JA, **Gabriel SE**, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care* 2002;25(3):583-92. [Review]
2. Boers M, Dijkmans BAC, **Gabriel SE**, Maradit Kremers H, O’Dell JR, Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. *Arthritis Rheum* 2004; 50(6):1734-9.
3. Vanness DJ, Tosteson AN, **Gabriel SE**, Melton LJ III. The need for microsimulation to evaluate osteoporosis interventions. *Osteoporosis Int* 2005;16:353-8.
4. \*Davis JM III, Maradit Kremers H, **Gabriel SE**. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? *J Rheumatol* 2005;32(10):1856-62.
5. \*Liang KP, **Gabriel SE**. Autoantibodies: innocent bystander or key player in immunosenescence and atherosclerosis? *J Rheumatol* 2006;34(6):1203-7.
6. **Gabriel SE**. Do antirheumatic drugs increase the risk of acute myocardial infarction? [Practice Point Commentary] *Nat Clin Pract Rheum* 2007;3(1):12-3.
7. Khan MA, Clegg DO, Deodhar AA, **Gabriel SE**, Hill Gaston JS, Hirsch R, Ostergaard M, Reveille JD, Turkiewicz AM, Weisman MH, Davis JC. 2006 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). [Meeting Report] *J Rheumatol* 2007;34(5):1118-24.
8. **Gabriel SE**. Heart disease in rheumatoid arthritis: changing the paradigm of systemic inflammatory disorders. [Keynote address] *J Rheumatol* 2007;34(1):220-3.
9. Solomon DH, **Gabriel SE**. Moving forward with quality: pay for reporting meets rheumatology. *Arthritis Care Res* 2007;57(5):703-4.
10. Solomon DH, **Gabriel SE**. Quality Measures 101: what every rheumatologist should know. *Exp Rheum*

2007;25(46):18-21.

1. **Gabriel SE**. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis. *Arthritis Rheum* 2008;58:637-40.
2. Solomon DH, **Gabriel SE**. A call for evidence-based quality measures: a goal worthy of pursuit. *Nat Clin Pract Rheum* 2008;3(7)363.
3. Solomon D, Tyndal A, **Gabriel SE**, Dougados M. Rheumatology gone global. *Ann Rheum Dis* 2008; 67(10):1357.
4. **Gabriel SE**. Heart disease and rheumatoid arthritis: understanding the risks. [Manuscript from a presentation at 2009 “Advances in Targeted Therapies”]. *Ann Rheum Dis* 2010;69:i61-i64.
5. **Gabriel SE.** Shaping our own future: 2009 American College of Rheumatology Presidential Address. *Arthritis Rheum* 2010;62(2):307-10.
6. Adebajo A, **Gabriel SE**. Addressing musculoskeletal health inequity in Africa. [Editorial] *Arthritis Care Res*

2010;62(4):439-41.

1. Gelijns AC, **Gabriel SE**. Looking beyond translation – Integrating clinical research with medical practice. *N Engl J Med* 2012;366(18):1659-61. PMCID – NA.
2. **Gabriel SE**, Normand SL. Getting the methods right – Foundations for patient-centered outcomes research. *N Engl J Med* 2012;367(9):787-90.
3. **Gabriel SE**. Educating the Workforce for a Transformed Clinical Research Enterprise. Commentary, Institute of Medicine, Washington, DC. 2012. [http://www.iom.edu/Global/Perspectives/2012/EducatingtheWorkforce.aspx.](http://www.iom.edu/Global/Perspectives/2012/EducatingtheWorkforce.aspx)
4. Kitas GD, **Gabriel SE**. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. *Ann Rheum Dis* 2011;70:8-14. [Review] PMCID – NA.
5. Symmons D, **Gabriel SE**. Epidemiology of cardiovascular disease co-morbidity in rheumatic disease, with a focus on rheumatoid arthritis and systemic lupus erythematosus. *Nat Rev Rheumatol* 2011;(7):399-408. [Review]. PMCID – NA.
6. Crowson CS, **Gabriel SE**. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. *Ann Rheum Dis*. 2011;70(5):719-21. PMCID; PMC3907170
7. Kremers HM, Myasoedova E, Crowson CS, Savova G, **Gabriel SE**, Matteson EL. The Rochester Epidemiology Project; exploiting the capabilities for population-based research in rheumatic diseases. *Rheumatol* (Oxford). 2011;50(1):6-15. PMCID: PMC3716332.
8. **Gabriel SE**, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. *Curr Opin Rheumatol*

2012;24(2):171-6. [Review] PMCID – NA.

1. Mankad R, **Gabriel SE**. Rheumatoid arthritis: treating cardiovascular risk in RA requires multidisciplinary care.

*Nat Rev Rheumatol* 2014;10(4):202-4. [Review] PMCID – NA.

1. **Gabriel SE**, Benefactors Help Mayo Medical School Become Reality in Arizona. *Mayo Clinic Magazine* 2014; 28(2): 23. PMCID – NA.
2. Symmons D, **Gabriel SE**. Epidemiology of cardiovascular disease co-morbidity in rheumatic disease, with a focus on rheumatoid arthritis and systemic lupus erythematosus. *Nat Rev Rheumatol* 2011;(7):399-408. [Review]. PMCID – NA.
3. Crowson CS, **Gabriel SE**. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. *Ann Rheum Dis*. 2011;70(5):719-21. PMCID; PMC3907170
4. Kremers HM, Myasoedova E, Crowson CS, Savova G, **Gabriel SE**, Matteson EL. The Rochester Epidemiology Project; exploiting the capabilities for population-based research in rheumatic diseases. *Rheumatol* (Oxford). 2011;50(1):6-15. PMCID: PMC3716332.
5. **Gabriel SE**, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. *Curr Opin Rheumatol*

2012;24(2):171-6. [Review] PMCID – NA.

1. Mankad R, **Gabriel SE**. Rheumatoid arthritis: treating cardiovascular risk in RA requires multidisciplinary care.

*Nat Rev Rheumatol* 2014;10(4):202-4. [Review] PMCID – NA.

1. **Gabriel SE**, Benefactors Help Mayo Medical School Become Reality in Arizona. *Mayo Clinic Magazine* 2014; 28(2): 23. PMCID – NA.

# Letters

1. **Gabriel SE**. Prescribing patterns in the rheumatic diseases. [Letter] *J Rheumatol* 1992;19(3):502.
2. **Gabriel SE**. Prophylaxis of NSAID gastropathy. [Letter] *J Rheumatol* 1992;19(4):662.
3. **Gabriel SE**, O'Fallon WM, Kurland LT. Reply to letters on “Risk of connective-tissue diseases and other disorders after breast implantation.” [Letter] *N Engl J Med* 1994;331(18):1233-4.
4. Katz JN, Liang MH, **Gabriel SE**, Cleary PD. Features of male vs. female patients undergoing surgery for osteoarthritis: comment on two recent articles. [Letter] *Arthritis Rheum* 1995;38(3):448.
5. **Gabriel SE**. Prescribing patterns in the rheumatic diseases. [Letter] *J Rheumatol* 1992;19(3):502.
6. **Gabriel SE**. Prophylaxis of NSAID gastropathy. [Letter] *J Rheumatol* 1992;19(4):662.
7. **Gabriel SE**, O'Fallon WM, Kurland LT. Reply to letters on “Risk of connective-tissue diseases and other disorders after breast implantation.” [Letter] *N Engl J Med* 1994;331(18):1233-4.
8. Katz JN, Liang MH, **Gabriel SE**, Cleary PD. Features of male vs. female patients undergoing surgery for osteoarthritis: comment on two recent articles. [Letter] *Arthritis Rheum* 1995;38(3):448.
9. **Gabriel SE**. “Risk of connective-tissue diseases and other disorders after breast implantation.” [Letter] *Life Sci*

1995;57:1737-40.

1. \*Salvarani C, **Gabriel S**, Hunder GG. Reply to “Comparison of polymyalgia rheumatica and remitting seronegative symmetrical synovitis with pitting edema syndrome [Letter] *Arthritis Rheum* 1996;39(11):1932.
2. **Gabriel SE**, Hunder GG, Salvarani C. Reply to “Giant Cell Arteritis.” Comment on article by Salvarani et al. [Letter] *Ann Internal Med* 1996;124(10):928.
3. \*Achkar AA, Hunder GG, **Gabriel SE**. Reply to letter, “Effect of Previous Corticosteroid Treatment on Temporal Artery Biopsy Results.” [Letter] *Ann Internal Med* 1998;128(5):410.
4. \*Achkar AA, **Gabriel SE**, Hunder GG. Reply to letter, “Facial Pain and Giant Cell Arteritis.” [Letter] *J Rheumatol*

1998;25(6):1242-3.

1. **Gabriel SE**, Peterson LS, Mason TG, Nelson AM, O’Fallon WM. Reply to letter, “Psychosocial outcomes and health status in adults who have had juvenile rheumatoid arthritis.” [Letter] *Arthritis Rheum* 1998;41(10):1898-9.
2. **Gabriel SE**. Reply to letter, “Trends in the Incidence and Mortality of SLE.” [Letter] *Arthritis Rheum*

1999;42(9):2021-2.

1. Guillemin F, **Gabriel SE**. Reply to letter, “Cost effectiveness analysis -- assessing the assumptions behind the assumptions.” [Letter] *J Rheumatol* 2000;27:1565-7.
2. Proven A, **Gabriel SE**, Hunder GG. Reply to letter, “Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.” [Letter] *J Rheumatol* 2000;27(7):1815-6.
3. Proven A, **Gabriel SE**, Hunder GG. Reply to letter, “Polymyalgia rheumatica with low erythrocyte sedimentation rate.” [Letter] *J Rheumatol* 2000;27(9):2283.
4. **Gabriel SE**, Reply to letter, “Trends in mortality of patients with rheumatoid arthritis.” [Letter] *J Rheumatol*

2000;27(9):2283-4.

1. **Gabriel SE**, Veale D. The epidemiology of psoriatic arthritis (multiple letters). *J Rheumatol* 2001;28(3):678.
2. \*Montori VM, Basu A, Erwin PJ, **Gabriel SE**, Kudva Y. Post-transplantation diabetes: a systematic review of the literature. [Letter] *Diabetes Care* 2002;25(9):1667-8.
3. \*Davis JM III, Roger VL, Crowson S, Maradit Kremers H, Therneau TM, **Gabriel SE**. [Letter: Reply to comment regarding The Presentation and Outcome of Heart Failure in Subjects with Rheumatoid Arthritis Differs from that of the General Population. *Arthritis Rheum* 2008;58(9):2603-11.
4. \*Kermani TA, Schafer VS, Crowson CS, Hunder GG, **Gabriel SE**. Increase in Age at Onset of Giant Cell Arteritis: A Population-based Study [Letter]. *Ann Rheum Dis* 2010;69(4):780-1.
5. Matteson EL, Crowson CS, **Gabriel SE**. Nontraditional risk factors in coronary heart disease. [Letter]. *Ann Intern Med* 2010;152(6):405.
6. **Gabriel SE**, Crowson CS. Ischemic heart disease and rheumatoid arthritis: comment on the article by Holmqvist et al. [Letter] *Arthritis Rheum* 2010;52(8):2561.
7. Mankad R, **Gabriel SE**. Treating cardiovascular risk in RA requires multidisciplinary care. *Nature Reviews Rheumatology*. April 2014;10(4):202-4. PMID: 24637364.